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Tau is a microtubule stabilizing protein that forms aggregates in Alzheimer’s disease (AD). Tau 
protein abnormal aggregation is one of the main pathological features in AD patients’ brain, 
particularly in the forms of insoluble tau fibrils. However, in recent years, a more prominent role in 
pathogenesis and diagnosis of AD has been increasingly given also to soluble tau oligomers and tau 
fragmentation pathways as well. 
It was previously shown that fragmentation is linked to oligomeric stress in murine models of 
tauopathy, as co-expression of fragmented and full-length tau in tau transgenic mice results in the 
formation of oligomeric, non-fibrillary tau species and causes severe paralysis. This paralysis is fully 
reversible once expression of the tau fragment is halted, even though mutant tau expression is 
maintained. Whereas various strategies to target tau aggregation have been developed, little is 
known about the long-term consequences of reverted tau toxicity. 
Tau fragments constitute also the majority of the protein reaching the cerebrospinal fluid (CSF) 
compartment. CSF-derived tau is a key diagnostic biomarker for AD; however, its features are largely 
unknown. Particularly, it is an unresolved question whether CSF-derived tau possesses a seeding 
competence. Previous in vivo studies on CSF-derived Aβ proved that this other biomarker does not 
have a seeding potential; however, in vitro studies on CSF-derived tau pointed towards another 
direction. Therefore, it was investigated whether CSF collected from patients diagnosed with 
probable AD or mild cognitive impairment (MCI) likely due to AD harbors a prion-like tau seeding 
potential. 
The present thesis shows that tau species can be neurotoxic in the absence of seeding-competent 
tau aggregates, and mice can clear these tau forms permanently without tau seeding or spreading 
effects. These observations suggest that early targeting of non-fibrillar tau species may represent a 
therapeutically effective intervention in tauopathies. On the other hand, the absent seeding 
competence of early toxic tau species also warrants caution when using seeding-based tests for 
preclinical tauopathy diagnostics.  
The results of the thesis provide also first evidence for in vivo prion-like properties of AD patients’ 
CSF, accelerating tau pathology in susceptible tau transgenic mice. This demonstrates that 
biologically active tau seeds reach the CSF compartment in AD. Further studies may help to evaluate 
strain specific properties of CSF-derived tau bioseeds, and to assess their diagnostic potential.  
In conclusion, the results presented in the thesis follow therefore nascent lines of research where 
oligomers are questioning the importance of established hallmarks in neurodegenerative diseases, 
and oligomerization might be indeed linked to fragmentation of protein at the center of neurological 




call for the importance and specificity of tau biomarkers for AD diagnosis, and this newfound seeding 

























1.1) Alzheimer’s disease (AD) 
Dementia is a deteriorating process which involves memory, thinking, behavior and the ability to 
perform daily activities (WHO, 2015). In 2015, dementia cases have been accounted up to almost 
50 million people in the world; among these, 60-70 % are hypothesized to be caused by the 
neurodegenerative disease known as Alzheimer’s disease (AD) (WHO, 2015). It has been estimated 
that, by 2050, the number of people affected by AD will triple compared to present days (Hebert et 
al, 2013). Nowadays, AD is the sixth leading cause of death in US (Heron, 2016) and the mortality 
rates of the disease are also increasing constantly (Taylor et al, 2017). This neurological disorder is 
usually divided in late onset AD (LOAD) and early onset AD (EOAD), with the first form being 
accounted for more than 90 % of cases (Blennow et al, 2006). AD is phenotypically characterized 
by a slow, but progressive and unstoppable cognitive decline, starting from early mnemonic 
difficulties, difficulties in word-finding, and complex behavioral changes (Mucke, 2009). 
Histologically, the disease is characterized mainly by two types of pathological hallmarks. The first 
ones are amyloid-beta (Aβ) plaques, cleaved pathological products of the amyloid precursor protein 
(APP), and those are specific traits for AD (Murphy & LeVine, 2010). The second ones are 
neurofibrillary tangles (NFT), a pathological type of tau filaments which are distinctive of a group of 
diseases called tauopathies (Goedert & Spillantini, 2006).  
AD is a multifactorial disease, and its pathogenesis is far from being clarified, but there is a general 
better understanding of risk factors (Ballard et al, 2011). A significant increase of the presence of the 
apopoliprotein E4 allele (ApoE4, on chromosome 19) has been proven in LOAD patients and it has 
been deemed as the highest known genetic risk factor for developing the disease (Sadigh-Eteghad 
et al, 2012). Other known mutations in EOAD include those regarding genes coding for APP on 
chromosome 21), presenilin 1 (PSEN1, on chromosome 14) (Campion et al, 1999) and 2 (PSEN2, 
on chromosome 1) (Lanoiselée et al, 2017), with the last two forming half of the gamma-secretase 
complex which helps cleaving APP into the smaller Aβ fragments (Kaether et al, 2006).  
The specific pathogenicity of Aβ, the EOAD-causing mutations on APP and the enzymes which 
cleave it, and the higher occurrence of AD in people affected by Down syndrome, caused by a 
trisomy on the same chromosome 21 which contains the APP gene, all led to the amyloid hypothesis 







1.2) Amyloid hypothesis and Aβ role in AD 
As stated before, the reasons and the mechanisms behind AD development are not fully understood; 
however, the amyloid hypothesis, postulated in 1991 (Hardy & Alisop, 1991) and based on the 
fundamental role of the cleaved fragment Aβ from its precursor protein (APP), has been generally 
debated as the most likely and detailed (although not complete or conclusive) theory on the cause 
of AD (Selkoe & Hardy, 2016), therefore giving rise to an enormous field of research on Aβ and its 
progenitor APP.  
APP is a single-pass transmembrane glycoprotein with a large N-terminal extracellular domain and 
a shorter C-terminal cytoplasmic tail (O’Brien & Wong, 2011). It is important to report that its role is 
unknown, and that APP loss by itself has not been proven as deleterious (O’Brien & Wong, 2011). 
APP undergoes through a proteolytic processing which branches in two different pathways, 
amyloidogenic and non-amyloidogenic, with the first one giving birth to the neurotoxic Aβ cleaved 
fragment (O’Brien & Wong, 2011). The amyloidogenic pathway needed for the cleavage of APP into 
Aβ involves processing by β-secretase 1, also known as β-site APP-cleaving enzyme 1 (BACE-1) in 
the extracellular domain, at the residue corresponding to the β-cleavage site, generating the soluble 
APP-β (sAPPβ) ectodomain, that starts with the N-terminus of Aβ and a 99-residues membrane-
associated peptide (C99) (Thinakaran & Koo, 2008). A second cleavage is executed by γ-secretase, 
on variable sites of the sAPPβ (usually after 40 or 42 residues from the beginning of it), leaving the 
Aβ fragment (Thinakaran & Koo, 2008). The most fibrillogenic isoforms of Aβ are the 40 and 42 
residues long, particularly the latter (Murphy & Levine, 2010), whose C-terminus allows for a faster 
formation of pathogenic oligomers (Bitan et al, 2003). Aβ has been shown to aggregate and spread 
through connected brain regions, and spread the amyloid deposition (Langer et al, 2011). 
It is widely accepted that Aβ has at least a proven correlation with AD, and it is central for the 
comprehension of the pathophysiology of AD (Herrup, 2015). However, there are many evidences 
against the amyloid hypothesis and the centrality of Aβ for the development of AD (Ricciarelli & 
Fedele, 2017). One of the main concerns is that amyloid deposition does not seem to correlate well 
to the AD and dementia phenotypes, as histological tests proved (Murphy & LeVine, 2010). 
Particularly, amyloid deposition has been shown not to be parallel to memory and cognitive 
impairment (Villemagne et al, 2011), but mostly related to functional network disruption, as per 
Electroencephalography (EEG) and Magnetic Resonance Imaging (MRI) measurement (Pievani et 
al, 2011). Later, positron emission tomography (PET) studies further confirmed that Aβ deposits do 
not correlate well with the degree of cognitive impairment (Landau et al, 2016). Furthermore, even 
though Aβ has been shown to be cytotoxic in vitro (Ono et al, 2009), no neuronal cell death has been 




It is important to report that drugs targeting Aβ and the enzymes processing it, such as beta-site APP 
cleaving enzyme (BACE) inhibitors, γ-secretase inhibitors and antibodies against Aβ have all proven 
ineffective, sometimes even worsening cognition (Mullard, 2019a). In fact, more than 100 drugs 
directed against Aβ have failed to elicit a significant clinical improvement (Becker & Greig, 2012). 
More in detail, some of these drugs have managed to decrease Aβ levels in the brain, but none of 
these showed clinical efficacy (Giacobini & Gold, 2013) with the researchers incurring into failures 
from different directions  (Mehta et al, 2017). As an example, anti-aggregant drugs against amyloid 
plaque formation, such as tramiprosate, reduced the plaque load in animal models but failed to meet 
clinical endpoints when administered to patients (Aisen et al, 2011). Also acting on the secretases 
processing APP was not successful: a few clinical trials involving BACE inhibitors ended in failure 
due to excessive liver toxicity (Barão et al, 2016), while the ones involving γ-secretase inhibitors did 
not manage to have the drugs marketed, due mainly to very low blood-brain barrier (BBB) 
penetrance (Green et al, 2009; Coric et al, 2012). Finally, also monoclonal antibodies against Aβ 
failed in clinical trials: among many cases, emblematic is Lilly’s Solanezumab, which targeted Aβ 
central epitope, necessary for its oligomerization (Watt et al, 2014). This monoclonal antibody did 
not improve the cognitive decline in clinical trials and resulted in possible complications such as 
edema (Honig et al, 2018). The drug was even resurrected for further trials once it seemed to slow 
down disease progress, but it was later definitively dropped after failing again to meet the desired 
clinical endpoints (Knopman, 2019). 
A possible explanation for this series of failure for drugs targeting Aβ is that the amyloid burden is 
not parallel to cognitive impairment, as many diagnostic techniques have confirmed (Pievani et al, 
2011; Landau et al, 2016). More in detail, the missing correlation of Aβ with cognitive decline in 
symptomatic phase of dementia (Mehta et al, 2017) could be meaning that the drugs against Aβ are 
administered too late in time, because Aβ might start the pathogenic cascade of events leading to 
AD, but that same cascade continues independently of it (Selkoe & Hardy, 2016). Another 
explanation behind the failure of drugs acting on the amyloid cascade is the involvement of β and γ-
secretases in pathways different from APP processing (Barão et al, 2016), therefore suggesting that 
they might be unspecific targets for treating AD (Ricciarelli & Fedele, 2017). 
Consequently, other targets for possible drugs against AD have been hypothesized, and the role of 
Aβ in AD development has been questioned by researchers, who consider that tau protein could 
have a more prominent role for the pathological mechanism behind AD, compared to Aβ (Makin, 
2018), especially due to the better correlation of the other main pathological hallmark of AD, NFTs, 






1.3) Tau protein  
Tau is a microtubule-associated protein encoded by chromosome 17, with the role of stabilizing the 
microtubules and promote axonal outgrowth (Wang & Mandelkow, 2016), through a complex 
equilibrium between phosphorylation and dephosphorylation (Pasinetti et al, 2010). It is a very 
hydrophilic and highly soluble protein (Wang & Mandelkow, 2016). Overall, the protein is basic, 
possessing an acidic N-terminus and a neutral C-terminus, separated by a proline-rich motif (Wang 
& Mandelkow, 2016). There are six possible isoforms in humans, generated by alternative splicing 
of exons 2,3 and 10 out of the 16 included in the MAPT gene encoding tau (Wang & Mandelkow, 
2016) The protein is formed by two near amino-terminal inserts and four repeat domains; the six 
isoforms are formed by a variable number of near amino-terminal inserts (0N,1N or 2N) and the 
presence or absence of the second repeat domain (Wang & Mandelkow, 2016).  
 
Fig.1: tau isoforms and structures. Differential splicing of exons 2 and 3 and exon 10 yields the 6 different isoforms of 
human tau, with 0,1 or 2 near amino-terminal inserts and the expression or not of the second repeat domain. Adapted from 
Wang & Mandelkow, 2016. 
 
Tau is expressed mainly in the neurons of the central nervous system (CNS), but also in astrocytes 
and oligodendrocytes (Shin et al, 1991). After its discovery in 1975, tau has been almost immediately 
characterized as an intrinsically disordered protein (Cleveland et al, 1977). Although it is natively 
unfolded, its natural state shows little tendency for aggregation; however, paired helical filaments 
(PHF) and the previously cited NFT are pathological hallmarks common to many neurodegenerative 
diseases usually known as tauopathies, which include chronic traumatic encephalopathy (CTE), 
progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), argyrophilic grain disease 
(AGD), Pick’s disease, and frontotemporal dementia and parkinsonism linked to chromosome 17 
(FTDP-17) (Goedert & Spillantini, 2006). Generally, tauopathies occur sporadically, but the 
mechanisms behind the accumulation on each disease are poorly understood (Rojas & Boxer, 2016). 
Tau pathological role has been clearly elucidated by the mutations causing FTDP-17, which resulted 




towards a more prominent attention on the microtubule stabilizer. It has also been reported that tau 
lesions are common features in Lewy bodies, pathological hallmarks of the group of diseases known 
as synucleopathies, which comprise Parkinson’s disease (PD), the second most frequent 
neurodegenerative disease in the world behind AD (Moussaud et al, 2014). Therefore, tau is getting 
increasingly important as a possible therapeutic target in neurodegenerative disorders. 
1.3.1) Tau function 
As mentioned before, Tau was discovered in 1975 as part of the family of microtubule-associated 
proteins (Weingarten et al, 1975). It is a heat-stable protein, and later it has been characterized as 
a microtubule stabilizer, essential for microtubule assembly from tubulin (Cleveland et al, 1977). 
More in detail, stability of the microtubules is obtained by a complex equilibrium of phosphorylation 
and dephosphorylation of tau (Pasinetti et al, 2010) with tau detaching from microtubules when 
phosphorylated (Billingsley & Kinkaid, 1997). It has been estimated that 99 % of tau is bound to 
microtubules in mature neurons (Congdon et al, 2008). Tau interacts with the microtubules through 
the repeat domains and flanking regions (Wang & Mandelkow, 2016) at the interface of tubulin 
heterodimers (Kadavath et al, 2015); more in detail, the repeat domains are microtubule-binding 
domains, while the flanking regions play a regulatory role in this interaction (Mukrasch et al, 2007). 
Different aminoacidic sequences among the repeat domains regulate the different affinity of the 
microtubule-binding domains to the microtubules (Guo et al, 2017). By stabilizing said microtubules, 
it allows cytoskeleton re-organization (Feinstein & Wilson, 2005), and it might not be the only function 
tau accomplishes while bound to microtubules, as it is thought to regulate axonal transport through 
various mechanisms (Wang & Mandelkow, 2016). Among these mechanisms, the common feature 
is that tau slows down axonal transport by competing for binding sites on microtubules with kinesin 
(mostly) and dynein (Stamer et al, 2002), which would then act as motor protein in this process. 
However, most of these mechanisms have been shown in vitro, but have been unparalleled so far 
in vivo, with tau deletion not affecting axonal transport in murine models (Yuan et al, 2008). 
Tau does not bind to microtubules only; in vitro studies showed tau interactions with the 
ribonucleoproteome, chaperones, the proteasome, histone complexes, and members of the 14-3-3 
protein family (Gunawandana et al, 2015) but also neural DNA (Sultan et al, 2011). These 
interactions show other possible functions of the protein: as an example, tau has been proven to be 
play a role for translation both in vitro and in vivo, as a negative regulator. (Papanikolopoulou et al, 
2019) Another tau function which has gotten increasing attention during recent years is tau protective 
role for neural DNA, as proven per in vitro studies (Sultan et al, 2011). In fact, tau has been shown 
to protect neural DNA from heat-induced stress in neuronal cultures (Sultan et al, 2011). Interactions 
of tau pave the way also for eventual hypotheses of the pathological mechanisms behind tauopathies 
(Wang.X et al, 2019). Tau has been proven to interact to non-myosin muscle proteins, and this link 




which have been proven to be disrupted in presence of mutated P301L tau in vitro (Wang.X et al, 
2019).  
More complicated functions of tau in neurological pathways have also been prospected, based on 
in vivo observations. Experiments in Drosophila led to the association of tau to long-term sensorial 
memory, particularly to negative regulation of olfactory memory and facilitation of habituation 
(Papanikolopoulou et al, 2019), a common neural plasticity phenomenon which sees a decrease of 
innate responses once a stimulus is repeated over time (Zuo et al, 2017). Altogether, tau first proven 
role remains the most studied and clarified over the years, but more studies must be executed to 
better understand the other less highlighted functions of the proteins. 
 
1.3.2) Tau post-translational modifications 
As it happens many other proteins, tau undergoes through a number of post-translational 
modifications (PTM), with the most frequent being phosphorylation (Neddens et al, 2018), just like it 
happens for the majority of the proteins (Khouri et al, 2011). Tau phosphorylation has a clear role for 
the development of tauopathies, through heterogeneous spreading and misfolding pathways 
(Dujardin et al, 2018) and will be described separately. However, tau can also be modified by the 
means, among others, of glycosylation, acetylation, deamidation, isomerization, nitration, 
methylation, ubiquitylation, and sumoylation (Martin et al, 2011). PTMs on tau can have variable 
outcomes: proving this concept, N-glycosylation can promote tau filamentous aggregation and 
hyperphosphorylation (Congdon & Sigurdsson, 2018), while O-GlcNAcylation, catalysed by the O-
GlcNAc transferase (OGT) (Gorelik et al, 2019) acts in a protective way against fibrilization of tau, 
negatively regulating phosphorylation due to occupation of the phosphorylation sites (Gong et al, 
2016). Furthermore, the interplay between these modifications can have an impact on AD pathology 
(Losev et al, 2019), as they normally co-exist in a dynamic equilibrium (Yuzwa et al, 2008), which is 
disrupted in AD (Losev et al, 2019).  
Among the many PTMs occurring to tau protein, tau acetylation is one of the most studied PTMs 
(Cohen et al, 2013), with controversial results over the years: some researchers believe in its 
protective potential (Carlomagno et al, 2017), while other studies brought up its contribution to tau 
aggregation (Cohen et al, 2013). While deacetylation catalysed by histone deacetylase 6 (HDAC6) 
leads to aggregation (Cook et al, 2014), the p300 acetyltransferase usually acts on the same sites 
of HDAC6, thus suggesting another interplay between enzymes which can regulate tau propensity 
to aggregate (Cook et al, 2014). Tau acetylation on Lys321 also negatively switches off tau 
hyperphosphorylation in vitro (Carlomagno et al, 2017); however, previous studies have found out 
that p300 acetyltransferase could also increase tau aggregation by possibly impairing tau 




p300 acetyltransferase is correlated with cognitive decline (Min et al, 2015), so the impact of 
acetylation on development of tauopathies depends on the acetylated site (Wang & Mandelkow, 
2016). It is curious to report that tau can auto-acetylate itself, as it possesses acetylation properties 
(Cohen et al, 2013). Altogether, these findings suggest that the role of the various PTMs on tau is 
far from being elucidated, thus leading the researchers to study the more established tau 
hyperphosphorylation phenomenon as a possible target for therapeutic intervention. 
 
1.3.2.1) Tau phosphorylation 
As previously mentioned, the most common form of post-translational modification occurring to tau 
is phosphorylation, with the protein exhibiting more than 70 possible phosphorylation sites (Neddens 
et al, 2018). The phosphorylation sites of tau reside mainly in the flanking regions of the proteins, 
and most of these easily accessible to kinases, especially serine/threonine kinases (Martin et al, 
2011), due to its natively unfolded structure (Wang & Mandelkow, 2016). Other phosphorylation sites 
in or near the repeat domains are targeted for phosphorylation by microtubule affinity-regulating 
kinases (MARKs) cyclic AMP-dependent protein kinase (PKA) and calcium or calmodulin-dependent 
protein kinase II (CaMKII), among others (Hanger et al, 2009). Generally, the kinases acting on tau 
phosphorylation sites can be summarized in three broad groups (Martin et al, 2011). The first one is 
formed by proline-directed protein kinases (PDPKs), which are serine/threonine kinases and include 
glycogen synthase kinase-3 (GSK-3), cyclin-dependent kinase-5 (Cdk5) and mitogen-activated 
protein kinases (MAPKs) (Martin et al, 2011). The second one is formed by non-PDKs, which are 
serine/threonine kinases including cAMP-dependent protein kinase A (PKA), casein kinase 1 (CK1) 
and microtubule affinity-regulating kinases (MARKs) (Martin et al, 2011). Finally, the last one is the 
group of protein kinases specific for tyrosine residues including Src, Fyn, Abl, and Syk (Martin et al, 
2011) 
As said before, tau regulates microtubule stability keeping a complex balance between 
phosphorylation and dephosphorylation (Pasinetti et al, 2010), with tau dephosphorylation able to 
enhance microtubule assembly and tau phosphorylation decreasing the affinity of the protein for 
microtubules (Martin et al, 2011). Tau phosphorylation has also been proven to detach the protein 
from actin (Whiteman et al, 2009) and it also modifies the protein interactions with cytoplasmic 
membrane, DNA, Fyn and other binding partners, which can result to a range of impaired signaling 
pathways (Hanger et al, 2009). Other physiological functions of tau phosphorylation, besides its role 
for balancing microtubule assembly, are far from being fully clarified, but this post-translational 
modification has been linked also to induced hypothermia and lethargic status (Luppi et al, 2019). A 
possible explanation for this phenomenon is that phosphatases are more sensitive to temperature 




There are also few suggestions on tau phosphorylation being possibly neuroprotective: as an 
example, phosphorylation on Ser422 is known to impair tau truncation at Asp 421 (Guillozet‐
Bongaarts et al, 2006), which is one of the most studied pathological cleavages occurring at C-
terminus of tau (Ozcelik et al, 2016). There are also tau phosphorylation sites, like Thr 205, which 
have been shown to protect against Aβ toxicity in murine models of AD (Ittner et al, 2016). However, 
tau phosphorylation is still mostly and predominantly known for its pathological contribution to 
neurodegeneration (Neddens et al, 2018). 
 
Fig.2: tau phosphorylation sites. The figure shows all putative phosphorylation sites and also the epitopes of the most used 
antibodies for detection of these phosphorylation sites. (Simic et al, 2016) 
 
The role of tau hyperphosphorylation in pathological conditions has been extensively studied 
throughout the years, as the link between tau hyperphosphorylation and its ability to self-assemble 
has been thoroughly established (Guo et al, 2017). In fact, it is known that hyperphosphorylation of 
tau can provoke self-assembly of the protein into filamentous, pathological forms, which are at the 
center of tauopathies (Guo et al, 2017). Generally, it has been established as a 3-fold minimum 
increase of tau phosphorylation compared to controls (Neddens et al, 2018), and in some of the 




(Wang.J et al, 2013). In AD, particularly, tau hyperphoshorylation has been shown to result in 8-10 
phosphorylated sites per tau molecule (Wang.J et al, 2013).  
The exact process behind the formation of NFT has not been clarified yet, even though it is known 
that tau hyperphosphorylation alone is not sufficient to its aggregation (Wang & Mandelkow, 2016), 
as there are also phosphorylation events which protect against tau accumulation, such as 
phosphorylation at Thr205 (Ittner et al, 2016). The aggregation into filamentous tau is suspected to 
be provoked by unknown cofactors (Wang & Mandelkow, 2016), and also other PTMs are thought 
to contribute to formation of fibrils, such as the aforementioned N-glycosylation (Congdon & 
Sigurdsson, 2018). Nonetheless tau hyperphosphorylation is necessary for the aggregation into 
filamentous forms, as it detaches tau from microtubules and releases soluble tau that can aggregate 
afterwards (Martin et al, 2011).  
Phosphorylation sites constituted by Ser-Pro or Thr-Pro motifs in the flanking regions are usually 
hyperphosphorylated in tauopathies and they get targeted for phosphorylation by several signal-
transducing proline-directed serine/threonine kinases (Wang & Mandelkow, 2016), the first of the 
three aforementioned groups of kinases acting on tau phosphorylation sites. These phosphorylation 
events can detach tau from microtubules (Wang & Mandelkow, 2016), as it happens with 
phosphorylation of the sites in the repeat regions by non-PDKs group of kinases (Hanger et al, 2009). 
However, phosphorylation sites differ significantly in their impact on tau affinity for microtubules: 
phosphorylation at Thr231 or Ser262, as an example (Alonso et al, 2010) are known to greatly reduce 
tau affinity for microtubules and therefore are more likely to release soluble tau which could then 
form fibrils, while other phosphorylation sites do not have the same impact on the microtubule affinity 
of the protein (Ando et al, 2016). 
From a clinical point of view, there are also phosphorylation sites with a higher relevance: as an 
example, Thr181 is the most frequent phosphorylated site measured in clinical AD samples 
(Lathuilière et al, 2017). Other clinically relevant phosphorylation sites are Ser202 and Thr205, which 
together constitute the AT8 antibody epitope, recently established for immunohistochemical post-
mortem analysis of possible AD patients (Braak et al, 2006). This epitope is also important for the 
understanding of structural changes related to hyperphosphorylation, as tau undergoes through a 
conformational change defined by phosphorylation of Ser202 and Thr205 altogether which is thought 
to lead to higher aggregation propensity (Despres et al, 2017). However, as mentioned before, 
phosphorylation of Thr205 alone has been shown to protect against formation of plaques (Ittner et 
al, 2016). 
In summary, tau hyperphosphorylation remains a hot topic in the development of neurodegenerative 
disorders, but the impact of the single phosphorylation events can greatly vary, and altogether the 




1.3.3) Tau mutations 
More than 80 mutations have been identified referring to tau protein (Wang & Mandelkow, 2016). 
Many of these are pathogenic, linked to tauopathies such as FTDP-17 (Goedert & Spillantini, 2000), 
CBD (Kouri et al, 2014) and PSP (Coppola et al, 2012). It has been hypothesized that tau mutations 
can become pathogenic by changing the ratio between 3R and 4R tau, possibly increasing tau 
phosphorylation (Lacovich et al, 2017). However, it is not rare that many missense mutations change 
the ratio of tau isoforms without resulting in pathogenic tau mutated forms, effectively being “benign” 
mutations (Guerreiro et al, 2010). It is important to report that, while AD is the most common 
tauopathy occurring in the planet (Goedert & Spillantini, 2006), there is no tau mutation conclusively 
linked to the AD phenotype (Ghetti et al, 2015) although many mutations in MAPT gene have been 
occasionally observed in AD patients (Van Giau et al, 2019).  
The majority of tau mutations happen in the microtubule-binding regions and tend to decrease tau 
affinity to the microtubules (Wang & Mandelkow, 2016). Many missense mutations tend instead to 
have an effect on tau alternative splicing (Ghetti et al, 2015), and the same outcome occurs with 
intronic mutations, usually clustered at the intron following exon 10 of MAPT gene (Ghetti et al, 
2015). There are also mutations which affect tau in a more subtle way, as it happens with the ones 
hindering the interaction with the dynactin complex (Magnani et al, 2007): these mutations take place 
at exon 1 of MAPT gene, and they are thought to disrupt axonal transport (Magnani et al, 2007).  It 
has been hypothesized that many of tau mutations lead to loss of function of tau, which would then 
trigger neurodegenerative processes (Ghetti et al, 2015). Generally, despite the common 
acceptance of tau mutations affecting post-translational modification, interaction with other proteins, 
and a variety of intracellular processes, the full complexity of the mutations occurring to tau has yet 
to be untangled (Guo et al, 2017). The next section will therefore be dedicated to elucidate tau most 




Tauopathies are the group of diseases characterized by tau inclusions in neurons and glia (Götz et 
al, 2019), with the main common consequence resulting in dementia and neurodegeneration 
(Kovacs, 2015). Tauopathies are categorized by the brain regions affected by tau inclusions, the 
dominant tau isoform that is part of the inclusions, the morphology of said inclusions and the cell 
types involved in the neurodegenerative processes (Götz et al, 2019).  
From a clinical point of view, tauopathies have been divided into primary and secondary sub-types, 




other clinical features (Crary et al, 2014). Primary age-related tauopathies (PARTs) therefore do not 
include AD, but only those tauopathies who depend solely on tau inclusions (Crary et al, 2014) and 
are a subgroup of frontotemporal lobar degeneration (FTLD) dementia forms (Van Mossevelde et al, 
2018).  Among the PARTs, the most characterized ones are progressive supranuclear palsy (PSP), 
corticobasal degeneration (CBD), argyrophilic grain disease (AGD), Pick’s disease (Goedert & 
Spillantini, 2006), and globular glial tauopathy (GGT) (Chung D.E.C et al, 2019). It is definitely worth 
mentioning that FTDP-17 was the first dementia form directly linked to defined pathological tau 
mutations (Goedert & Spillantini, 2000), and proving that tau dysfunction can independently cause 
neurodegeneration, with more of 30 tau mutations identified (Goedert & Jakes, 2005). However, 
dementia forms caused by these mutations have been now considered as genetic sub-categories of 
PARTs (Forrest et al, 2018), and so the term FTDP-17 has been mainly discontinued. 
 
Fig.3: list of main tauopathies affecting human brains, divided by pathological tau isoform, pathological hallmarks and 
eventual associations with other pathological hallmarks. Tauopathies in the yellow boxes predominantly show 3R tau 




as predominant ones. Straight lines indicate primary tauopathies, while dotted lines show secondary ones (Rösler et al, 
2019) 
 
Among tau inclusions, neurofibrillary tangles are the most prominent and known ones, but the range 
of tau inclusions is heterogeneous (Guo et al, 2017). A very important feature they possess is that 
they can be experimentally transmitted (Clavaguera et al, 2009). Injections of brain homogenates of 
mice containing tau fibrils in transgenic murine models proved that tau pathology can be seeded in 
a prion-like manner, as tau aggregates spread in brain regions anatomically connected to the site of 
the injection even in wild type mice (Clavaguera et al, 2009). The experiment was also replied with 
the injection in mice of human brain homogenates of various tauopathies-affected patients, and 
tangles were again spreading from the site of injection towards the closer brain regions (Clavaguera 
et al, 2013), thus proving that tau is self-propagating, and its seeding competence is manifested in 
a prion-like manner (Clavaguera et al, 2013). There is extensive research being carried out to 
discover the features of tau seeding, particularly related to the most seeding-prone sequences in the 
protein (Stöhr et al, 2017), and some of the most self-aggregating tau sequences seem to be 
concentrated in the third repeat region of tau (Stöhr et al, 2017); however, tau seeding competence 
is probably independent of strain isoform compositions and the 3R/4R ratio, but it is instead intrinsic 
to unique pathological conformations (He et al, 2020). 
Among the many pathological conformations of tau coming from tauopathies, the globular 4R tau 
inclusions coming from GGT have shown the stronger seeding-competence, compared to other brain 
lysates coming from tauopathies such as AD, CBD and PSP (Chung D.E.C et al, 2019). These 
inclusions typical of GGT can be found in oligodendrocytes and astrocytes, and they are composed 
of highly hyperphoshorylated tau inclusions affecting frontal and temporal lobes (Götz et al, 2019). 
Tau inclusions in astrocytes are the main features of PSP and CBD, which respectively show tufted 
astrocytes and astrocytic plaques, both composed of twisted fibers of hyperphosphorylated 4R tau 
(Kovacs, 2015), with pathological tau structures of CBD affecting mostly the forebrain and the ones 
of PSP affecting mainly the hindbrain (Dickson, 1999). AGD inclusions are also mostly composed of 
hyperphosphorylated 4R tau (Götz et al, 2019) but they are mainly pre-tangle stage grains in the 
oligodendrocytes of limbic regions (Tolnay & Clavaguera, 2004). The grains distinctive of AGD can 
be considered as immature tangles and they have been shown to be less seeding-competent 
compared to the brain lysates of the other tauopathies (Clavaguera et al, 2013). The only tauopathy 
which sees a prevalence of 3R tau inclusions is Pick’s disease, characterized by Pick’s bodies, 
seeding-competent rounded structures mainly found in frontal and temporal lobes (Saijo et al, 2017). 
Tauopathies are therefore variegated and constitute an unsolved puzzle for researchers, as the 




secondary tauopathy, AD, which also sees Aβ playing a role in the disease; however, tau is assuming 
a more prominent role in present studies, and it will be described in the next section. 
 
1.3.4.1) AD and tau involvement 
Alzheimer’s disease (AD) can be described as a secondary tauopathy, as it is distinguished not only  
by fibrillary tau inclusions but also by amyloid plaques (Götz et al, 2019). However, it is important to 
report that tau pathology is more closely related to cognitive deficits and brain atrophy than Aβ 
plaques, as proven recently by PET experiments (La Joie et al, 2020). It is also important to report 
that senile plaque involvement advances in a different way compared to the progression of 
pathological tau in the brain (Braak & Braak, 1991) and does not correlate to cognitive decline as 
well as the progression of tau pathology (Bejanin et al, 2017). 
 
1.3.4.1.1) Tau tangles 
Tangles are the most common neuronal inclusions in AD, and they are composed of insoluble twisted 
fibrils of both hyperphosphorylated 3R and 4R Tau (Götz et al, 2019). Punctate Tau aggregates are 
at first deposited in the cell bodies and dendrites, where they convert into pre-tangles (Götz et al, 
2019), a premature form of NFTs which consists of granular cytoplasmic deposits (Kinoshita et al, 
1998). These then mature into aforementioned NFTs and then transform into extracellular tangles 
over decades (Götz et al, 2019). It is curious to report that tangles have been known as one of the 
main pathological hallmarks of dementia for more than a century (Alzheimer, 1906), but tau was 
identified more than 80 years later as the protein composing the harmful tangles (Grundke-Iqbal et 
al, 1986), more than a decade after being identified as a microtubule stabilizer (Weingarten et al, 
1975). Tau pathology can propagate in AD patients from one brain region to another in specific 
patterns (Braak & Braak, 1997); moreover, injection of recombinant tau fibrils has been proved to 
provoke formation of NFTs propagating from the injection site to connected brain regions in a time 
dependent manner (Iba et al, 2013). Therefore, even if the process originating the formation of NFTs 
is still unknown (Umeda et al, 2014), their spreading potential is established and contributes to the 
worsening of the disease (Braak & Del Tredici, 2016).  
The progression of AD is classified into six stages, known as Braak stages, based on the distribution 
of tangles in the brain (Braak & Braak, 1991). These six stages can be further categorized into three 
categories, corresponding to the regions in which the tangles are distributed: transentorhinal (I and 
II), limbic (III and IV) and neocortical (V–VI) stage groups, corresponding to normal cognition, 




stages of Alzheimer’s disease, as tau accumulates first in the hippocampus and entorhinal cortex, 
and then spreads to neighbouring regions (Lace et al, 2009). Damages to the hippocampus have 
been shown to affect memory (Bird & Burgess, 2008), though it is not known exactly how this brain 
region is related to the mnemonic processes (Bird & Burgess, 2008), but the expression of new 
memories is correlated to the hippocampal-entorhinal connectivity (Takehara-Nishiuchi, 2014). Tau 
proposed spreading pattern is thought to start from subcortical areas, continuing to the 
transentorhinal cortex, limbic system and neocortex (Braak & Del Tredici, 2016). Particularly, limbic 
system is involved in attention and emotional processes (Li. X et al, 2016), explaining also 
behavioural problems in AD patients (Mittelman et al, 2006). 
 
1.3.4.1.2) Tau oligomers 
Tau fibrils are however not the only pathogenic conformation of tau in AD, as oligomeric tau species 
contribute significantly to the toxicity of tau in neurodegenerative disorders (Cowan et al, 2010; 
Gerson et al, 2014) and they have been proven to cause severe neurotoxicity in transgenic tau 
murine models without the presence of tangles (Oczelik et al, 2016). Tau oligomers have been 
proven to appear in the brain of AD patients (Lasagna-Reeves et al, 2012). These oligomers have 
been shown to correlate well with neuronal death in aged mice (Lasagna-Reeves et al, 2011), unlike 
tangles (Gomez-Isla et al, 1997; Andorfer et al, 2003). Moreover, oligomers are generally thought to 
initiate disease development in tauopathies (Lasagna-Reeves et al, 2012) and even to appear before 
the first clinical symptoms (Maeda et al, 2006). Tau oligomers have also shown the capability to 
spread tau pathology from affected regions of the brain to the unaffected ones (Wu et al, 2013). 
Antibodies specifically targeting tau oligomers proved effective in murine models, reducing locomotor 
and memory deficits without affecting tangles (Castillo-Carranza et al, 2014). Particularly, preventing 
early tau aggregation from monomers into oligomeric species was shown to be a possibly efficient 
therapeutic approach (Castillo-Carranza et al 2014). Altogether, these observations lead 
researchers to believe that tau oligomers are the main responsible behind neuronal dysfunction 
(Polanco et al, 2018).  
Tau oligomers have been shown to anticipate NFT formation (Takashima, 2013). However, their 
toxicity is relevant also regardless of tangles, as studies have proven that in murine models tau 
toxicity can be either halted in presence of NFTs (Santacruz et al, 2005), or it can be elicited in 
absence of tangles (Cowan et al, 2010; Ozcelik et al, 2016). It is of particular interest that the 
aforementioned severe neurotoxicity caused by tau oligomers, even without the presence of tangles, 
is obtained in murine models by the interaction between tau fragments and full-length mutant tau, 
and even by tau fragments interacting with full-length wild type tau (Ozcelik et al, 2016). It is also 




overexpression in murine models can stop the formation of oligomers and the related severe motor 
dysfunction (Ozcelik et al, 2016). This brings more attention to the possible role of tau fragmentation 
for the development of tauopathies, and it will be treated in depth in the following chapters. 
 
 
1.4) Fragmentation in neurodegenerative diseases 
Neurodegenerative disorders are mostly associated with abnormal, pathological protein aggregation 
processes, thus they have been categorized as proteinopathies (Walker & LeVine, 2012). So far, the 
mechanisms behind this pathological aggregation processes in proteinopathies have been only 
partially explained, with many different factors suspected to participate and lead to pathological 
phenotypes (Walker & Levine, 2012). Proteins which are already biologically prone to aggregation 
have an increased tendency to cause pathological folding and form pathological aggregates: 
mutations, such as those commonly found in hereditary forms of proteinopathies, can increase the 
probability of a protein becoming aggregation-prone (De Baets et al, 2015). In sporadic diseases, 
instead, the induction of pathological aggregation processes has remained only partly understood. 
In many neurodegenerative diseases, protein fragments, derived by different cleavage patterns, 
could play a prominent role in their development and further advancement. There are many 
examples of small aggregation-prone fragments that can have a pathogenic role for 
neurodegenerative disorders such as Alzheimer’s diseases (AD)(Hardy & Alisop, 2001); familial 
British and Danish dementia (FBD, FDD) (Ghiso et al, 2001; Rensink et al, 2003); Parkinson’s 
diseases (PD) (Li.W et al, 2005); TDP-43 related disorders (Li.Q et al, 2015) and triplet expansion 
disorders such as Huntington disease (HD) (Wellington et al, 2002).  
The causes behind the fragmentation of the proteins generating the aggregation-prone fragments 
are generally debated, both in role and mechanism; there are mutations resulting in altered cleavage 
processes in hereditary variants of neurogenerative diseases, such as presenilin mutations in AD 
(Campion et al, 1999; Lanoiselée et al, 2017), but in sporadic cases the mechanisms behind protein 
fragmentation remain to be fully understood. Furthermore, the neurotoxicity of these processes in 
proteinopathies is still debated, as the contribution of cleaved fragments to the neurodegenerative 
disorders remains difficult to establish; particularly, it has still to be determined whether the protein 
fragmentation is one of the steps causing the diseases, or it is just a side effect. However, their 
presence in these types of disorders is proven, although in different forms.  
Fragments participate to the protein aggregates in neurodegenerative disorders in different ways, 
either alone, or in complex with the full-length protein from which they derive. The first case is 




al, 1999); the second case is exemplified by α-synucleinopathies (Dufty et al, 2007) or TDP-43 
related disorders (Zhang. Y et al, 2009). Tau belongs to the second category (Ozcelik et al, 2016) 
and undergoes through many different cleavage processes which will be illustrated in the next 
section. 
1.4.1) Tau fragmentation 
Tau possesses a variety of cleavage sites which can yield truncated forms of the protein (Martin et 
al, 2011). Proteolytic processing of tau by a variety of endogenous proteases has been studied for 
its possible involvement in development of tauopathies (Rissman et al., 2004). Studies on tau 
aggregation revealed that truncated forms of tau are part of the core of paired helical filaments 
(PHFs) (Fitzpatrick et al, 2017). Furthermore, fragmented tau has been reported to increase the 
propensity of tau to convert into fibrils (Abraha et al., 2000); however, tau fragments have also been 
shown to provoke the formation neurotoxic oligomers, in concert with mutant tau or wild-type tau 
(Ozcelik et al, 2016). Therefore, tau fragmentation is getting an increasing importance for AD and 
tauopathies’ development. 
1.4.1.1) Tau fragmentation in AD 
 
Fig.4: tau cleavage sites. Figure shows all identified truncation sites; figure A shows the sites for which the proteolytic 
enzyme has been identified, while figure B shows all the sites for which the cleaving enzyme has yet to be identified (Quinn 





Recently, it has been proven that the plaques alone are not sufficient for tau conversion into its 
pathological form, and tau fragmentation has been identified as the other necessary factor for the 
plaque-guided conversion of tau into its pathological aggregated form (Li.T et al, 2016). Furthermore, 
the expression of tau truncated form has been established to induce highly (but reversibly) neurotoxic 
in presence of full-length tau (Ozcelik et al, 2016), thus strongly implying that tau cleavage could 
play a crucial role in tauopathies and AD progression, influencing both plaques and NFT 
pathogenicity. 
Tau fragmentation occurs in various and different processes among the various cells and brain 
tissues, as it can be cleaved in different sites by many proteolytic enzymes such as caspases, 
calpains, thrombin, cathepsins and PSA (puromycin-sensitive aminopeptidase) (Hanger & Wray, 
2010). Cleavage sites were predicted at both C-terminal and N-terminal domains of tau, and the 
truncation was catalyzed mainly by caspases (Delobel et al, 2008). C-terminal proteolytic processing 
of tau in human AD brains was first observed at Glu391, with no enzyme being clearly linked to its 
cleavage (Novak et al, 1993). This tau fragment has been studied in the mice models Tau E391 and 
it is present in both NFT and PHF, while also driving pathological changes in pre-tangle stages 
(McMillan et al, 2011), and more generally it is linked to clinical dementia (Basurto-Islas et al, 2008). 
The recently obtained cryo-EM structural characterization of PHF in AD brains also confirmed that 
tau truncated at Glu391 is part of the structural core of these pathological hallmarks (Fitzpatrick et 
al, 2017). Also of note for tau fragmentation pathogenicity, this same study has confirmed that PHF 
and straight filaments (SF) are mainly composed by tau fragments corresponding to repeat domains 
3 and 4 (Fitzpatrick et al, 2017), and that same tau 4R domain has been shown to induce Aβ plaque-
guided conversion of tau in seeding-prone form (Li.T et al, 2016). 
Nowadays, one of the most studied cleavage processes is the one occurring at Asp421 (D421), 
associated with caspases 3 (Rissman et al, 2004) and 6 (Guo et al, 2004). This tau fragment has 
been studied in the mouse model Tau 62/48 (Ozcelik et al, 2016). Many roles in neurodegenerative 
processes have been proposed for tau cleaved at D421: it is part of NFTs (Zhang et al, 2014), and 
it also induces severe, but reversible neurotoxicity in AD mouse models when co-expressed with full-
length tau (Ozcelik et al, 2016). Tau cleaved at D421 is not an exclusive pathological feature of AD, 
but it is also found in other tauopathies, such as Pick’s disease (Mondragon-Rodriguez et al, 2008). 
More generally, when transfected in vitro, this tau fragment has been shown to induce cell death 
significantly more than full length tau (Chung C.W. et al, 2001), while in vivo accumulation of it 
correlates with AD and disease progression in mouse models of tauopathies and non-AD patients, 
e.g in FTDP-17T patients (Basurto-Islas et al, 2008).  
N-terminal cleavage of tau is less clarified, at least in vivo; in vitro, caspase 6 cleaves tau at Asp13 
(D13) site (Chung C.W. et al, 2001), which is likely to be physiologically significant for AD 




stages of the disease (Horowitz et al, 2004) and cleaved forms of tau at D13 site are increasingly 
present in more severe stages (Ghosal et al, 2002). It has also been proposed that tau forms cleaved 
at D13 temporally correlate with the appearance of tau species cleaved at D421 (Horowitz et al, 
2004). It has to be said that, although caspase cleavage sites are not fully explained, their activity 
and the processing of tau leading to its truncated forms clearly precede NFT formation in mouse 
model Tg4510 (De Calignon et al, 2012). This has led to theories that greatly emphasize the role of 
tau truncation by caspases over tangle formation, with truncated tau (particularly at D421) recruiting 
full-length tau to misfold and successively participate to aggregates (De Calignon et al, 2012). 
Recently, it has been shown that the major tau species in human cerebrospinal fluid (CSF), and 
more generally in extracellular fluids, are N-terminal truncated forms, mainly cleaved at the end of 
the mid-domain between residues 222 and 225 (Sato et al, 2018). In the same study, tau production 
has been directly linked to progression of amyloid disease (in form of amyloid plaques burden) in AD 
brains, so it is likely that N-terminal truncated tau forms elicit an important role in AD progression in 
vivo too (Sato et al, 2018). 
Altogether, tau fragmentation remains a possible explanation for many pathological developments 
of AD by probably being involved in the formation of filamentous tau (Wang. Y et al, 2009) and, more 
generally, leading to a possible toxic gain of function (Guo et al, 2017). There are still many 
unexplained points on how tau fragmentation participates to AD pathological mechanisms, but the 
evidence is generally growing towards a more prominent role of tau fragments in contributing to 
neurotoxicity. Further studies will be required to clarify more in detail what tau cleavage process add 
to the development and progression of neurodegenerative disorders. 
Furthermore, it can also be crucial for AD diagnosis, as CSF tau is among the most reliable 
biomarkers for AD diagnosis (Simonsen et al, 2017) and tau fragments constitute the majority of 
CSF tau conformations (Sato et al, 2018), with some researchers going as far as telling that full-
length tau is practically absent in the  CSF of AD patients (Meredith Jr et al, 2013). AD diagnosis 




1.5) AD diagnosis 
Since the first histological observation of the disease in 1906, the diagnosis of AD has remained 
controversial as, even nowadays, it can be established with 100 % certainty only with post-mortem 
analysis of the brain, thanks to the identification of neurofibrillary tangles and amyloid plaques 




can be wrongly suspected in life or, to the contrary, escape detection of clinical experts (Reed et al, 
2007). A first official, reliable and organized list of criteria for a likely AD diagnosis was published in 
1984 (McKhann et al, 1984) by the Alzheimer’s Association, and it has been revised several times 
recently (Dubois et al, 2007; McKhann et al, 2011).  
Altogether, AD diagnosis pre-mortem has been established with a good certainty, and it has been 
officially established according to cognitive tests, brain imaging, and biomarkers (McKhann et al, 
2011). A battery of cognitive tests has been devised over the years. One of most established one to 
test cognitive impairment is the Mini-Mental State Examination (MMSE) (Tsoi et al, 2015); however, 
Mini-Cog test and the ACE-R have also a good reliability among the various dementia tests (Tsoi et 
al, 2015). It is important to mention also the Montreal Cognitive Assessment (MOCA) test, which has 
extensively been compared to the MMSE and seems to screen better for cognitive impairment 
(Ciesielska et al, 2016), and the Clinical Dementia Rating (CDR) scale, which is the most used 
numerical scale assessing dementia (Rosenberg et al, 2013).   
Imaging techniques applied to diagnose AD are mainly Magnetic Resonance Imaging (MRI) and 
Positron Emission Tomography (PET) (Simonsen et al, 2017). MRI detects brain atrophy, typical 
morphological change of AD patients (Long et al, 2017) which strongly correlates with Braak stages 
(Long et al, 2017) and it is a useful tool also for early diagnosis of AD (Long et al, 2017). PET instead 
can be useful to detect amyloid plaques in vivo, but it does not have complete precision for a 
diagnosis of AD because patients can also have a high amyloid burden without being affected by 
AD (Ossenkoppele et al, 2015). New PET tracers also gave the opportunity to detect tau pathology, 
and it is also strongly correlated with AD pathology, though not perfectly (Ossenkoppele et al, 2016).  
Finally, data from the clinical research increasingly support CSF biomarkers Aβ42, total tau (t-tau), 
and phosphorylated tau (p-tau) as biomarkers strongly related to AD pathological development, and 
they contribute with diagnostically relevant information (Blennow & Zetterberg, 2018). Other 
biomarkers, such as plasma tau and neurofilament light protein (NFL) have been also proposed to 
be helpful in AD diagnosis (Olsson et al, 2016), but the reliability of CSF biomarkers is much more 
established (Olsson et al, 2016), and the precision of the diagnosis based on the combination of the 
three core biomarkers is extremely high, detecting almost all the really affected patients analysed 
post-mortem (Shaw et al, 2009). It is known that CSF tau levels significantly increase in AD patients, 
while CSF Aβ levels are significantly lower (Blennow et al, 2001).  
The importance of biomarkers in AD diagnosis is debated, as sometimes ambiguous or 
indeterminate results can lead to confusion (McKhann et al, 2011). Particularly, it is important to 
report that AD biomarkers are more suited for diagnosis rather than screening (Frisoni et al, 2017), 
thus not helping the patients before the first insurgence of clinical symptoms. This is strengthened 
by the fact that Aβ deposits seem to appear much earlier than the first clinical symptoms (Selkoe & 




has been difficult to establish biomarkers in order to follow the hypothesized biochemical events that 
happen before the clinical manifestation of AD, particularly distinguishing aging-related mild 
cognitive impairment (MCI) from prodromal AD (Van Giau et al, 2019). 
Nonetheless, the reliability of biomarkers for AD diagnosis is nowadays increasing, with many clinical 
studies showing the levels of the aforementioned biomarkers being strongly related to the 
progression of the disease (Cohen et al, 2019; Scholl et al, 2018), with researchers going so far to 
propose even blood-tests related to said biomarkers, for the future (Zetterberg & Burnham, 2019). 
Altogether, evidence supports the claim that biomarkers will be increasingly important for AD 
diagnosis, even though more established guidelines have to be set. 
 
1.5.1) CSF biomarkers: Aβ 
As mentioned before, among the most important biomarkers for AD diagnosis there is Aβ42 CSF 
levels (Blennow & Zetterberg, 2018). Studies on the reliability of the biomarkers also tried to establish 
Aβ42 levels in plasma as a useful biomarker for AD diagnosis, but negative results stopped the 
attempt (Rival et al, 2009). As said before, CSF Aβ levels strongly decrease in AD patients compared 
to controls (Blennow et al, 2001), and particularly it is the earliest biomarker to change during the 
clinical course of the disease (Blennow & Zetterberg, 2018). The transmission of Aβ to the CSF 
compartment has been long established (Seubert et al, 1992), but the logic for CSF Aβ being 
significantly lower in AD patients escaped researchers at first (Andreasen et al, 1999). The 
pathophysiological basis for the reduction of CSF Aβ42 in AD was hypothesized to rely behind the 
fact that hydrophobic peptide aggregates are sequestered in plaques, with lower amounts remaining 
to be secreted to the extracellular space and the CSF, resulting in lower CSF levels of Aβ42 
(Andreasen et al, 1999). Post-mortem analysis of AD patients confirmed that a high burden of 
amyloid plaques was correlated with a low amount of Aβ42 in the CSF compartment (Strozyk et al, 
2003), and the inverse proportion between Aβ42 in the CSF and Aβ plaques was also later confirmed 
as well by brain imaging techniques (Fagan et al, 2006).  
Among the other isoforms of Aβ, the one which is 40 residues long (Aβ40) is the most abundant, 
with a concentration 10 times higher than Aβ42 (Olsson et al, 2016); even though it is so 
concentrated in the CSF, it shows no significant changes between controls and AD patients, thus 
being useless for the diagnosis (Olsson et al, 2016). However, it seems that the Aβ42/Aβ40 ratio 
could help the diagnosis of the disease in an even more relevant way than the simple CSF Aβ42 
levels (Lewczuk et al, 2017). The reason behind it is still unclear, and the ratio is still not considered 
officially (Dubois et al, 2007), but it seems that Aβ40 high load differentiates between patients having 
low CSF Aβ42 levels due to simple low amyloid production and patients that have low CSF Aβ42 




As mentioned before, Aβ is able to propagate amyloid aggregates through the brain (Langer et al, 
2011). Seeding capability of Aβ in the CSF compartment were also studied and seem to be weak, if 
non-existent (Fritschi et al, 2014; Skachokova et al, 2015). In a study comparing the seeding 
potential of CSF derived from AD patients to the diluted brain extracts from AD patients, the latter 
proved to spread amyloid deposition through the brain of APP transgenic mice, while the CSF-
derived Aβ was unable to do it (Fritschi et al, 2014). Similarly, CSF derived from those APP 
transgenic mice failed to provoke amyloid spreading in young pre-plaques stage APP transgenic 
mice (Fritschi et al, 2014), even after long period of concentration (Skachokova et al, 2015). The 
reason behind this lack of seeding capability was hypothesized to be the lack of N-terminally 
truncated amyloid-β species and the presence of smaller amyloid-β-positive particles (Fritschi et al, 
2014). However, even with the lack of seeding capabilities and the possible improvements derived 
from the reliability of the Aβ42/Aβ40 ratio, CSF Aβ remains a good diagnostic tool in concert with the 
other CSF biomarkers, particularly CSF tau (Olsson et al, 2016). 
 
1.5.2) CSF biomarkers: tau 
CSF tau levels are currently being used for clinical diagnosis of AD in conjunction with cognitive 
tests, brain imaging and CSF amyloid-β level measurements (Simonsen et al, 2017), with said levels 
significantly increased in AD patients compared to controls (Blennow et al, 2001). Pathologically 
modified tau forms are present in the extracellular space and can transfer between cells in the brain 
(Guo & Lee, 2014; Wu et al., 2013). Phosphorylated tau can be actively secreted via exosomal 
release, and reaches the CSF compartment (Saman et al, 2012). Ante mortem cerebrospinal fluid 
tau levels correlate with postmortem tau pathology in frontotemporal lobar degeneration (Irwin et al, 
2017); more in detail, increased tau levels in the CSF correlate best with cognitive decline in AD 
patients (Wallin et al, 2006).  
Experiments in vitro hinted at a possible seeding capability of CSF-derived tau in vitro: particularly, 
in vitro seeding activity of tau CSF has also been reported to induce high molecular tau aggregation 
in cell cultures (Takeda et al, 2016), with ventricular CSF samples collected post-mortem at 
autopsies of AD patients inducing tau aggregation in HEK293 cells expressing a P301S tau repeat 
domain (Takeda et a,. 2016). Furthermore, recent in vitro seeding assays demonstrated the ability 
of CSF tau to induce conformation changes in in vitro tau substrates (Saijo et al, 2017). More in 
detail, CSF tau derived from Pick’s disease patients has been found to induce real-time quacking 
induced conversion (RT-QuIC) of 3R tau fragment typical of Pick’s disease (Saijo et al, 2017). 





The detection of CSF tau levels in possible AD patients is one of the most reliable biomarker 
measurements in AD diagnosis nowadays, even compared with other biomarkers (Olsson et al, 
2016), but it lacks high specificity and is unable to help prognosis of the disease at early or even 
presymptomatic disease stages (Olsson et al 2016). Both total and phosphorylated tau are increased 
in the CSF of AD patients at later stages and can help predicting the scope of pathologic processes 
occurring in AD (Bateman et al., 2012). However, it is not clear whether higher CSF tau levels result 
from dying neurons and the related release of tau from the cells, from tau increased synthesis or tau 
decreased clearance (Sato et al, 2018). What is known is that CSF tau is mainly composed of tau 
fragments (Sato et al, 2018), and there is a strong likelihood that full-length tau is not capable of 
reaching CSF compartment, thus being in no part present in CSF (Meredith Jr et al, 2013). 
Particularly, tau species in CSF seems to be mostly composed by 20-40 kDa N-terminal fragments 
(Meredith Jr et al, 2013). As the attention on tau oligomers as targets for therapies against 
tauopathies is getting higher nowadays (Polanco et al, 2018), and tau oligomers are thought to 
appear even before the first clinical symptoms of AD (Maeda et al, 2006), it is important to report 
that tau oligomeric species seem to be part of CSF-derived tau (Sengupta et al, 2017). Particularly, 
tau oligomers increase in AD patients’ CSF and aggregate at different molecular weights (Sengupta 
et al, 2017). However, more precise data in vivo on said fragments and their structure needs to be 
acquired. 
Altogether, CSF-derived tau likely remains the most reliable biomarkers for AD diagnosis, and 
strongly advocates for the importance of fragmentation related to AD pathological mechanisms. 
However, the establishment of its seeding properties, the knowledge on how tau reaches the CSF 
compartment, the specificity of tau fragments in it and the structure of CSF tau remain mostly 
unknown to researchers, and can constitute an important improvement in the diagnosis of AD and 














2) Material and methods 
2.1) Mice 
Homozygous human P301S mutant tau transgenic mice (P301S tau mice) (Allen et al, 2002) were 
used as host mice for tau seeding experiments with human CSF. Transgenic homozygous mice 
expressing human ALZ17 mutant tau (ALZ17 mice) (Frank et al, 2008) were used as host mice for 
tau seeding experiments with brain stem homogenates from P301SxTAU62 mice. P301SxTAU62 
mice were obtained by interbreeding P301S mice and TAU62 mice (Ozcelik et al, 2016). TAU62 
mice express a human tau fragment from amino acid 151-421 (Δtau151-421) under doxycycline 
administration (Ozcelik et al, 2016). P301SxTAU62 mice were used for the investigation of potential 
long-term effects of neurotoxicity caused by tau oligomers along with their heterozygous littermates 
(P301Shet) which were never fed with doxycycline and therefore never expressed ∆tau151-421. Non-
transgenic C57BL/6J (BL6 mice) were used as control mice for behavioural tests. The mice were 
housed with a 12-hours light/dark cycle and permanent access to food and water. Animal 
experiments were approved by the official local Committee for Animal Care and Animal Use of the 
Canton of Basel (Licenses Nr. BS 2364 and 2471). 
 
2.2) CSF collection and patients’ characteristics  
In order to obtain large volumes of CSF from AD and control patients, allowing subsequent 
concentration, CSF was collected within a clinical trial set up in collaboration with the Memory Clinic, 
University Center for Medicine of Aging, Basel. The trial was approved by the local Ethics 
Commission of the Canton of Basel, and recruitment was limited to patients with a Mini Mental State 
(MMS) Score (Folstein et al, 1975) >19/30. All patients examined for memory disturbances and 
potential neurodegenerative disorders at the Memory Clinic were consecutively allowed to enter the 
study.  
Up to 15ml of CSF per patient were collected by lumbar puncture from a total of 23 subjects after 
obtaining written informed consent of the patient and a care-giver. Freshly collected CSF was spun 
at 3000 rpm for 30 minutes to remove cell debris. The supernatants were collected and frozen at 
−80° C. Clinical diagnosis was based on multimodal examinations including neuropsychological 
assessments, brain MRI imaging, CSF tau and Aβ level measurements. Brain perfusion SPECT 







2.3) CSF processing 
In order to obtain reasonable tau levels in small volumes that could be injected into mouse brains, 
CSF samples were concentrated (Skachokova et al, 2015). In brief, 10 ml CSF per patient, was 
lyophilized (−80° C, 0.01 mbar vacuum pressure), reconstituted in sterile H2O and dialyzed (using 
Float-A-Lyzer G2, 1kD, Spectrum Labs) to reduce the salt load, re-lyophilized, and finally 
reconstituted in about 10 l H2O. The final concentration of tau was measured by ELISA.  
 
2.4) ELISA 
CSF levels of tau, phospho-tau and A, were measured by commercial kits “Innotest hTAU AG”, 
“Innotest PHOSPHO-TAU”, and “Innotest β-Amyloid” (1-42) according to the manufacturer’s 
guidelines (Innogenetics/Fujirebio Europe N.V., Belgium) (Sunderland et al, 2003) 
 
2.5) Stereotaxic surgery 
For surgery, 3-months-old ALZ17 and P301S mice were anesthetized with a mixture of ketamine (10 
mg/kg) and xylazine (20 mg/kg) and placed on a heating pad to maintain body temperature. Mice 
were stereotactically injected into the right hippocampus (A/P, −2.5 mm from bregma; L, − 2.0 mm; 
D/V, −1.8 mm) using a Hamilton syringe. A unilateral stereotaxic injection of 5 μl concentrated CSF 
was performed on P301S mice, while brainstem homogenates of 6-months-old paralyzed 
homozygous P301S mice and 3-weeks-old paralyzed P301SxTAU62on mice were prepared for 
inoculation in ALZ17 mice. Brainstems were weighted and diluted 1:10 in PBS for seeding. After 
dilution, samples were homogenized using an Ultraturrax T8 (IKA Labortechnik, Staufen im 
Breisgau, Germany) and sonicated briefly (Bandelin SONOPULS, Bandelin, Berlin, Germany; 90% 
power, 10% cycle, 10 sec pulses). Homogenates were then centrifuged at 4000 g for 20 minutes at 
4 °C, and aliquots of the supernatant were stored at -70 °C for later usage. During inoculation, each 
mouse received 5 μl of brainstem homogenate at a speed of 1.25 μl/min. Following injection, the 
needle was kept in place for additional 3 minutes before withdrawal. The surgical area was cleaned 
with sterile saline and the incision sutured. Mice were monitored until recovery from anaesthesia, 
post-interventional analgesia was administered, and animals were checked regularly following 
surgery. After 20 months of incubation, the seeded mice were sacrificed. 
 
2.6) Behavioral tests 
Motor behavior, including gait ataxia, tremor, and hindlimb reflexes was assessed. Quantitative 
motor testing was performed by the grid test in which mice were placed on a vertical mesh grid and 




using the Panlab Harvard Rotarod (Harvard Apparaturs, Holliston, USA). The rotarod starts at a 
speed of 4 rpm and accelerates by 1 rpm every 3 sec. In both, grid test and rotarod assay, mice 
were tested for 3 consecutive days with 3 trials per day, with minimum rest intervals of 5 min, and 
the mean latency to fall was documented. Results were obtained by averaging the daily means of 3 
consecutive days. 
 
2.7) Sacrificing of mice and tissue preparation 
Mice were deeply anaesthetized with pentobarbital (150 mg/kg) and transcardially perfused with 20 
ml cold PBS. The brains were dissected and post-fixed overnight in 4% paraformaldehyde (PFA). 
Following paraffin embedding, 4 μm coronal sections were cut from the brain tissues of seeded mice, 
while 4 μm sagittal sections were cut from the brain tissues of the mice used for the behavioural 
tests. For Western blots and seeding material, the mice were only perfused with PBS, afterwards 
mouse brains were dissected and frozen in liquid nitrogen or on dry ice. 
 
2.8) Hematoxylin and Eosin staining 
Paraffin tissue sections were deparaffinized in xylene for 30 min and rehydrated through a series of 
EtOH/water solutions from 100 %, 96 %, 80 %, and 70 %, followed by dH2O, submerging the 
sections for 2 min each step. The rehydrated sections were stained with Harris’ hematoxylin (J.T. 
Baker, Biosystems Switzerland AG, Muttenz, CH), for 0.5 min, washed twice in dH2O and 
differentiated in 0.2 % HCl diluted in 70 % ethanol. Afterwards the Sections were stained in 1 % 
Erythrosine B (RAL DIAGNOSTICS, Biosystems Switzerland AG, Muttenz, CH), a stain closely 
resembling eosin Y, washed in dH2O and dehydrated through an ascending series of EtOH water 
solutions, form 70 %, 80 %, 100 %, followed by xylene. Subsequently the sections were mounted 
using Pertex (Histolab Products AB, Biosystems Switzerland AG, Muttenz, CH). 
 
2.9) Gallyas staining 
Tissue sections were silver-impregnated following the method of Gallyas-Braak to visualize 
filamentous tau pathology (Gallyas, 1971; Braak et al, 1988). Paraffin tissue sections were 
deparaffinized and rehydrated as described above. Afterwards the sections were incubated in 3 % 
periodic acid (w/v) for 30 minutes, rinsed in dH2O and incubated in alkaline silver solution (1 M 
NaOH, 0.6 M KI, 2 mM AgNO3) for 10 minutes. Subsequently the sections were developed by mixing 
developer solution A (0.5 M Na2CO3), solution B (24 mM NH4NO3, 12 mM AgNO3, 3.5 mM 




formaldehyde) in a ratio of 30:9:21 immediately before use, for ca. 25 minutes, simultaneous to 
monitoring of the reaction process.  
Solution Composition Concentration Supplier 
A 
Sodium Carbonate Anhydride 0.5 M Merck, Darmstadt, 
Germany 
B 
Ammonium nitrate 24 mM Merck, Darmstadt, 
Germany 
Silver Nitrate 12 mM Merck, Darmstadt, 
Germany 
Tungstosilicic Acid Hydrate 3.5 mM Sigma-Aldrich, St. 
Louis, USA 
C 
Ammonium nitrate 24 mM Merck, Darmstadt, 
Germany 
Silver Nitrate 12 mM Merck, Darmstadt, 
Germany 
Tungstosilicic Acid Hydrate 3.5 mM Sigma-Aldrich, St. 
Louis, USA 
Formaldehyde 3 % Merck, Darmstadt, 
Germany 
 
The developing was stopped via incubation in 0.5 % acetic acid for 30 minutes and fixed via 
incubation in 5 % Na2S2O3 for 3 minutes. The silver stained sections were rinsed in dH2O, 
counterstained using hematoxylin and Eosin, differentiated, dehydrated, and embedded as 
described on the previous page.  
 
2.10) Immunohistochemistry  
For immunohistochemistry, the following anti-tau antibodies were used: AT8 (1:1000, Pierce 
Biotechnology, Waltham, USA), AT100 (1:1000, Pierce Biotechnology, Waltham, USA), TauC3 
(1:1000, Santa Cruz Biotechnology, Santa Cruz, USA). Secondary antibodies were from Vector 
Laboratories, Burlingame, USA (Vectastain ABC kit). 4X, 10X, 20X and 40X magnified pictures of 
the stained slides were taken with an Olympus BX43 Upright Microscope (Life Sciences Solutions, 
Chicago, USA). 
For immunohistochemistry, paraffin tissue sections were deparaffinized and rehydrated as described 
for Hematoxylin and Eosin staining. For epitope retrieval the slides were placed in ProTaqs citrate 
buffer with pH 6 (BIOCYC, Potsdam, Germany) and microwaved for 30 minutes at 90 °C.  The 
secondary antibodies and peroxidase (HRP) substrate were from Vector Laboratories, Burlingame, 






2.11) Western blots 
For the western blots comparing total and soluble tau in 16-months-old P301S heterozygous 
(P301Shet) and P301SxTAU62on-off mice, brains were homogenized in cold extraction buffer 20 % 
(w/v) (25 mM Tris-HCl pH 7.4, 150 mM NaCl, 1mM EDTA, 1mM EGTA, 5 mM NaPyrophosphate, 10 
mM B Glycerophosphate, 30 mM NaFluoride, 10 mM NaVanadate, with addition of 100 ul/10 ml 
PMSF of 0.1 M just before use, and 1 Pierce protease and phosphatase inhibitor mini tablet, EDTA-
free, Pierce Biotechnology, Waltham, USA) using a Polytron Homogenizer (Thomas Scientific). An 
aliquot of the resulting homogenate was collected as total tau. Subsequently, samples were 
centrifuged at 80000 g for 15 min using an ultracentrifuge (Beckman Coulter, Brea, USA; OptimaTM 
L-70K Ultracentrifuge), and an aliquot of the supernatant was collected as soluble tau.  
For the western blot comparing total tau in 3-months-old mice, one half of the mouse brain was 
dissected into forebrain and brainstem, and frozen in liquid nitrogen or on dry ice. Brainstems were 
weighted and diluted 1:10 in TBS-Complete. Subsequently, samples were homogenized using an 
Ultraturrax T8 (IKA Labortechnik, Staufen im Breisgau, Germany) and briefly sonicated (Bandelin 
SONOPULS, Bandelin, Berlin, Germany; 90% power, 10% cycle, 10 sec pulses). Homogenates 
were then centrifuged at 4000 g for 20 minutes at 4 °C, and aliquots of the supernatant stored at -
70 °C for later usage.  
Western blots were then performed under non-reducing conditions using appropriate amounts of 
protein, 4X NuPAGE LDS sample buffer, and deionized water. 10X NuPAGE reducing agent was 
used to obtain reducing conditions. Following appropriate preparation, samples were loaded onto a 
7% NuPAGE® Tris-acetate gel. After the removal of gels from the cassette and activation of PVDF 
membrane (Amersham Biosciences, Amersham, UK) samples were transferred on the PVDF 
membrane using the XCell IITM Blot Module. Unspecific binding epitopes were blocked with 5% non-
fat milk in PBS-Tween, followed by incubation with primary antibody over night at 4°C on a shaker. 
After washing with PBS-Tween, the membrane was incubated with horseradish peroxidase (HRP)-
conjugated anti-mouse or -rabbit secondary antibody at room temperature. Then, the membrane 
was washed again in PBS-Tween and detected by electrochemiluminescence (ECL) (GE 
Healthcare, Little Chalfont, UK). The anti-tau antibody used for the western blots was HT7 (1:1000, 

























Thermo Scientific, Waltham 
USA 
GAPDH (6C5) GAPDH WB 1:1000 Santa Cruz Biotechnology, 
Santa Cruz, USA 
 
 
2.12) Dot blots 
For dot blots, serum of 3-months-old P301Shet and P301SxTAU62on-off mice was separated from the 
clot by centrifuging the samples at 1000 rpm for 15 minutes at 4 °C, with the remaining supernatant 
aliquoted and stored at -20 °C, for later usage. Then, a nitrocellulose membrane (Bio-Rad 
Laboratories, Inc., Hercules, USA) was divided in a grid to allow later incubations with 3-months-old 
P301Shet and P301SxTAU62on-off sera and HT7 antibody as positive control at 1:1000 dilutions. 0.2 
mg/ml of 2N4R wild-type tau monomers were applied on a 4x3 grid. Next, unspecific binding epitopes 
were blocked with 5% BSA in PBS-Tween, followed by a 30-minutes-long incubation at room 
temperature with previously extracted sera from the mice and HT7 antibody as positive control. After 
washing with PBS-Tween, the membrane was incubated with HRP-conjugated anti-mouse 
secondary antibody at room temperature, washed again in PBS-Tween, and detected by ECL (GE 
Healthcare, Little Chalfont, UK). 
 
2.13) Statistical analysis 
Quantifications were conducted on 4X, 10X, or 20X magnified images, taken with an Olympus BX43 
Upright Microscope (Life Science Solutions, Chicago, USA). Bregma levels were determined by 
visual comparison with the Mouse Brain Atlas (Franklin & Paxinos, 2008). The quantifications and 
the measurements of the area of the respective anatomical regions were performed by the Cell 
counter plugin in ImageJ (imagej.net). Brain images that were used and modified are from the Mouse 
Brain Atlas (Franklin & Paxinos, 2008).  
In order to estimate the effects of AD CSF tau seeds versus control seeds, mean values of 
counts/area ratios were calculated from the magnified images of AT8, AT100, and Gallyas positive 
neurons and dot-like structures, and p-values were obtained by t-tests. Three sections per animal 
were analyzed. P-values are interpreted exploratory and are not adjusted for multiple comparisons. 




To evaluate behavioral test results statistically, one-way analysis of variance (ANOVA) followed by 
post-hoc Student’s t-tests and Bonferroni correction for multiple comparisons were applied. P-values 
< 0.05 were considered significant.  
To estimate soluble tau and total tau expression from western blots of 3-months-old and 16-months-
old mice, the protein bands were normalized to GAPDH protein standard, and quantified using 
ImageJ software; generated mean ratio values were compared by Student’s t-test.  
To determine the effect of early neurotoxic stress in aged mice, AT8 and Gallyas-positive neurons 
were semi-quantitatively assessed in brainstem regions. Three sections per animal were analyzed. 
The average count/area ratios were obtained. P-values calculated by Student’s t-tests were 
interpreted exploratory and not adjusted for multiple comparisons; P-values < 0.05 were considered 
significant.  
Box plots were generated with R software. The lower and upper hinges correspond to the first and 
third quartiles (25th and 75th percentiles). The upper whisker extends from the hinge to the largest 
value no further than 1.5 times IQR from the hinge (where IQR is the inter-quartile range, or distance 
between the first and third quartiles). The lower whisker extends from the hinge to the smallest value 
at most 1.5 times IQR of the hinge. Data beyond the end of the whiskers are called "outlying" points 
and are plotted individually. 
 
2.14) Genotyping 
Compound Concentration Supplier 
Tris 100 mM (pH 8.5) Biomol, Hamburg, Germany 
EDTA 5 mM Fluka BioChemika, St. 
Gallen, Switzerland 
NaCl 200 mM Merck, Darmstadt, Germany 
SDS 0.2% Bio-Rad, Hercules, USA 
 
For sample digestion the thermomixer was set at 55 °C and 750 µl of tense buffer and 3,75 µl of 
Proteinase K were added to each sample. The samples were incubated overnight (or at least for 4 
hours) at 55 °C and 600 rpm.  
For DNA Isolation the samples were centrifuged at 4 °C and 14000 g for 5 minutes. A new tube for 
each sample was labelled and filled with 750 µl of isopropanol. Subsequently the supernatant was 
taken from each sample and added to the respective isopropanol tube. The tubes were then 




µl of 75% ethanol were added to each pallet. Next the samples were centrifuged at 4 °C and 14000 
g for 10 minutes. Afterwards the supernatant was discharged and 250 µl of sterile water were added 
to each tube. Subsequently the samples were incubated for 1 hour at 50 °C without shaking. 
For PCR 2.5 µl of each DNA sample were added to a PCR tube containing 22.5 µl of PCR mix (see 
table below). The primers and PCR programs for the Δtau allele and 4R tau allele (P301S tau 
detection) are sown below. 
For Gel electrophoresis 3 gels were prepared by mixing 300 ml of TAE-buffer with 4.5g of agarose 
in an Erlenmeyer Flask and heating the mixture in the microwave at maximum temp. for 4 minutes. 
Afterwards the mixture was cooled down for a couple minutes and 15 µl of cyber save were added. 
3 combs were placed in the gel chamber and the chamber was filled with the liquid gel. After 
solidifying the resulting gel was cut into 3 gels. For immediate use the gels were put in an 
electrophoresis chamber filled with TAE-buffer, 5 µl of loading dye were added to each sample and 
the samples were loaded to the gel. The gel was run in TAE-buffer for 1 hour at 150V (90 minutes 





12,5 µl Qiagen PCR Master mix Qiagen, Germany 
4 µl sterile water Qiagen, Germany 
2,5 µl forward primer Thermo Scientific, Waltham, USA 
2,5 µl reverse primer Thermo Scientific, Waltham, USA 
1 µl DMSO (add last) Merck, Darmstadt, Germany 
 
Primers 
Primer names Forward primer  Reverse Primer 
TauF151 (for Δtau detection) GTG GAT CTC AAG CCC 
TCA AG 
GGC GAC TTG GGT GGA 
GTA 
P301S (for 4R tau detection) GGT TTT TGC TGG AAT 
CCT GG 









TauF151 program P301S program 
Step 1: 95°C for 2 min Step 1: 95°C for 4 min 
Step 2: 95°C for 1 min Step 2: 95°C for 1 min 
Step 3: 60°C for 1 min Step 3: 60°C for 1 min 
Step 4: 72°C for 2 min Step 4: 72°C for 3 min 
Step 5: 72°C for 10 min (final extension) Step 5: 72°C for 10 min (final extension) 
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Tau is a microtubule stabilizing protein that forms aggregates in Alzheimer’s disease (AD). Tau derived from 
AD patients’ brains induces tau aggregation in a prion-like manner when injected into susceptible mouse 
models.  
Here we investigated whether cerebrospinal fluid (CSF) collected from patients diagnosed with probable AD 
or mild cognitive impairment (MCI) likely due to AD harbors a prion-like tau seeding potential. CSF was 
injected intrahippocampally into young P301S tau transgenic mice. CSF obtained from AD or MCI patients 
increased hippocampal tau hyperphosphorylation and tau tangle formation in these mice at 4 months post-
seeding. Tau pathology was also accentuated in the contralateral hippocampus, and in anterior and posterior 
directions, indicative of spreading.  
We provide first evidence for in vivo prion-like properties of AD patients’ CSF, accelerating tau pathology in 
susceptible tau transgenic mice. This demonstrates that biologically active tau seeds reach the CSF 
compartment in AD. Further studies may help to evaluate strain specific properties of CSF derived tau 













Tau is a soluble protein that promotes microtubule assembly in neuronal cells. However, in pathological 
conditions, it becomes hyperphosphorylated and forms intracellular aggregates. This is characteristic of 
Alzheimer’s disease (AD), but also of other neurodegenerative disorders known as tauopathies, including cases 
of frontotemporal dementia (FTD), corticobasal degeneration (CBD), and progressive supranuclear palsy 
(PSP) [36]. In AD, tau aggregation propagates from one brain region to another in specific patterns [6, 18, 20, 
21, 23]. It has been shown that tau pathology can be seeded in a prion-like manner, as the injection of brain 
extracts from tau transgenic donor mice or tauopathy patients into tau transgenic host mice causes tau 
aggregation in the inoculated mice [1, 8, 9, 24, 26, 27].  
Pathologically modified tau forms are present in the extracellular space and can transfer between cells in the 
brain  [10, 17, 40]. Phosphorylated tau can be secreted via exosomal release, and reach the cerebrospinal fluid 
(CSF) [32]. CSF tau levels are currently being used for the clinical diagnosis of AD in conjunction with 
cognitive tests, brain imaging and CSF amyloid-β (Aβ) level measurements [34]. Increased tau levels in the 
CSF correlate best with cognitive decline in AD patients.  
Information on the prion-like properties of Aβ and tau from CSF in AD is limited. It has been shown that CSF 
amyloid-β does not exhibit prion-like properties in vivo [16, 35]. Recently, two studies reported a seeding-like 
potential of CSF-derived tau in vitro [31, 38]. It is however not known, whether tau-comprising CSF harbors 
seeding potential in vivo.  
Here, we studied the in vivo seeding capacity of CSF derived from AD patients upon inoculation into P301S 
tau transgenic mice. These animals develop tau hyperphosphorylation and neurofibrillary tangles (NFT) when 
ageing. We collected CSF from patients diagnosed with probable AD or mild cognitive impairment (MCI) 
likely due to AD, and injected it into young P301S tau mice. As a result, we observed a significant increase in 
neurons positive for hyperphosphorylated tau, and an accelerated formation of Gallyas-Braak positive 
aggregates in the hippocampus, when compared to mice inoculated with CSF derived from elderly control 
patients. In parallel, there were signs of spreading of tau pathology along anatomical networks, in the form of 
hyperphosphorylated tau-positive neurons and dot-like structures, comparable to findings when seeding with 
brain-derived tau in P301S tau mice [1]. These findings provide first in vivo evidence for the presence of 






Materials and Methods 
Mice 
Homozygous human P301S mutant tau transgenic mice (P301S tau mice) [3] were used as host mice for all 
seeding experiments. Animal experiments were performed in compliance with protocols approved by the 
official local Committee for Animal Care and Animal Use of the Canton of Basel (License Nr. BS2471). 
 
CSF collection and patient characteristics 
In order to obtain large volumes of CSF from AD and control patients, allowing subsequent concentration, 
CSF was collected within a clinical trial set up in collaboration with the Memory Clinic, University Center for 
Medicine of Aging, Basel. The trial was approved by the local Ethics Commission of the Canton of Basel, and 
recruitment was limited to patients with a Mini Mental State (MMS) Score [14] >19/30. All patients examined 
for memory disturbances and potential neurodegenerative disorders at the Memory Clinic were consecutively 
allowed to enter the study. Up to 15ml of CSF per patient were collected by lumbar puncture from a total of 
23 subjects after obtaining written informed consent of the patient and a care-giver. Freshly collected CSF was 
spun at 3000 rpm for 30 min to remove cell debris. The supernatants were collected and frozen at −80° C. 
Clinical diagnosis was based on multimodal examinations including neuropsychological assessments, brain 
MRI imaging, CSF tau and Aβ level measurements. Brain perfusion SPECT imaging data was available on a 
subset of the patients.   
 
CSF processing 
In order to obtain reasonable tau levels in small volumes that could be injected into mouse brains, CSF samples 
were concentrated [35]. In brief, 10 ml CSF per patient, was lyophilized (−80° C, 0.01 mbar vacuum pressure), 
reconstituted in sterile H2O and dialyzed (using Float-A-Lyzer G2, 1kD, Spectrum Labs) to reduce the salt 
load, re-lyophilized, and finally reconstituted in about 10 l H2O (Suppl. Fig. 1). The final concentration of 








CSF levels of tau, phospho-tau and A, were measured by commercial kits “Innotest hTAU AG”, “Innotest 
PHOSPHO-TAU”, and “Innotest β-Amyloid (1-42)” according to the manufacturer’s guidelines 
(Innogenetics/Fujirebio Europe N.V., Belgium) [4, 37].  
 
Stereotaxic surgery 
Three month-old P301S tau mice were anaesthetized with a mixture of ketamine (10 mg/kg) and xylazine (20 
mg/kg) and placed on a heating pad to maintain body temperature during surgery. Mice were injected in the 
right hippocampus (A/P, −2.5 mm from bregma; L, − 2.0 mm; D/V, −1.8 mm) using a Hamilton syringe. Each 
mouse received a unilateral stereotaxic injection of 5 μl concentrated CSF, at a speed of 1.25 μl/min. Following 
the injection, the needle was kept in place for an additional 3 min. The surgical area was cleaned with saline 
and the incision sutured. Mice were monitored until recovery from anaesthesia, provided analgetic medication 
for up to 48 hours post-surgery, and checked regularly following surgery.  
 
Immunohistochemical analysis 
Four months post-inoculation, the mice were deeply anaesthetized with pentobarbital (150 mg/kg) and 
perfused with 20 ml cold PBS, followed by 20 ml 4% paraformaldehyde in PBS. The brains were dissected 
and post-fixed overnight. Following paraffin embedding, 5 μm thick coronal sections were prepared. Sections 
were silver-impregnated following the method of Gallyas-Braak to visualize filamentous tau pathology [7, 19]. 
Hematoxylin and eosin staining (H&E) was performed for morphological analysis. For tau 
immunohistochemistry AT8 (1:1000, Thermo Scientific), and AT100 (1:1000, Thermo Scientific) were used 
[29]. Secondary antibodies were from Vector Laboratories, Burlingame, CA (Vectastain ABC kit). 
For quantification, 3 brain tissue sections were analyzed at levels comprising the injection site (from -2 to -3 
m from bregma), and the number of Gallyas-Braak silver stained inclusions, AT8 and AT100 positive 
neurons (entire hippocampus) and dot-like structures (dentate gyrus (DG), fimbria) was counted on 4X, 10X, 




stainings, only 2 sections next to the indicated bregma levels were well preserved and usable for quantification. 
Bregma levels were determined by visual comparison with the Mouse Brain Atlas (Franklin and Paxinos, 
2007). The quantifications and the measurements of the area of the respective anatomical regions were 
performed by the Cell counter plugin in ImageJ (imagej.net). Brain images that were used and modified are 
from the Mouse Brain Atlas (Franklin and Paxinos, Elsevier 2007).  
AT8 positive neurons were furthermore semi-quantitatively assessed at various bregma levels in CA1, CA3, 
and dentate gyrus (DG) regions, and an average score was obtained. For the heatmap (Fig. 2), average tau 
pathology per bregma level was calculated and color-graded. 
Statistical analysis 
In order to estimate the effects of AD CSF tau seeds versus control seeds, mean values of counts/area were 
calculated, and p-values were obtained by t-tests. Data was collected from 3 to 6 seeded mice per group, 
depending on the stainings, as indicated in Suppl. Table 1. P-values are interpreted exploratory and are not 
adjusted for multiple comparisons. In the results section and the figures, mean values and standard deviations 
are indicated. A p-value < 0.05 was considered as significant. A comprehensive overview on the statistical 
data is provided in Suppl. Table 1.  
 
Data sharing 
All relevant clinical data on the patients included in this exploratory translational study is provided in table 1. 





CSF derived from AD patients accelerates cerebral tau pathology in P301S host mice.  
CSF collection: patients’ characteristics 
CSF was prospectively from a total of 23 patients visiting an outpatient Memory Clinic, in the setting of an 
explorative clinical trial. Up to 15ml of CSF were collected per patient without any relevant side effects. 
Clinical, imaging, and laboratory data of all patients were assessed. For experimental inoculation into 
transgenic mice, we selected CSF samples derived from the patients with the highest (“Alzheimer’s disease 
patients”: AD group, n=5) and the lowest (“control”-patients: CTR group, n=4) probability of AD-related 
cognitive decline. AD CSF samples were included from 2 patients fulfilling the actual criteria for “Probable 
AD dementia with high biomarker probability of AD etiology”, two patients with “Probable AD dementia with 
intermediate biomarker probability of AD etiology” [25], as well as one patient with “MCI - core clinical data” 
[2], the latter with high evidence for neuronal injury in the CSF analysis [2]. The 4 patients attributed to the 
CTR CSF group fulfilled the criteria for “Dementia-unlikely to be due to AD” (n=2) or “MCI-unlikely due to 
AD” (n=2), without biomarker evidence for AD [2, 25]. Detailed patients’ characteristics are provided in Table 
1. Cognitive decline of control patients was clinically attributed to non-neurodegenerative causes (e.g. vascular 
dementia or alcohol abuse). Mean age (CTR 67,8y/AD 71,6y, p=0,52) and MMS Score (27,3/24,2, p=0.10) 
did not significantly differ between the two groups, although there was a trend to a higher MMS in the patients 
attributed to the control patients’ group.   
Given the physiologically low tau concentrations in CSF in the ng/ml range, the samples were concentrated as 
previously described (Suppl. Fig. 1) [16, 35]. After concentration, no significant difference of the total tau 
levels between the two groups was measured by ELISA (156 ng/ml / 204,6 ng/ml, P=0.65, Suppl. Fig. 2).   
Hippocampal neuronal tau pathology provoked by AD-patients’ CSF 
Intrahippocampal injections of AD-patients’ CSF into young P301S tau mice resulted in an increased number 
of AT8 positive hippocampal neurons at the injection level, as compared to CTR CSF inoculated mice (Fig. 
1a-c, mean neuron count per area CTR CSF/AD CSF: 0,049/0,611, p=0,001, for comprehensive overview on 




in positive hippocampal neurons in the AD CSF injected hippocampus when compared to CTR CSF 
administered mice (Fig.1d-f,  CTR CSF/AD CSF: 0,101/0,729, p=0,013, for a detailed view on the accentuated 
AT8 and AT100 pathology in the CA1 field see Suppl. Figure 3). Moreover, a trend to increased tau 
phosphorylation was noticeable also in the contralateral, non-injected hippocampus, both for AT8 as well as 
for AT100 hyperphosphorylated tau, when comparing the CTR group to the AD group (AT8: 0,050/0,393, 
p=0,053, AT100: 0,164/0,626, p=0,053).  
Semi-quantitative analysis revealed more AT8 positive hippocampal neurons in AD CSF seeded mice anterior 
(from -2 to -2.5 mm) and posterior (from -2.5 to -3mm) to the injection site, compared to CTR CSF seeded 
mice, both, ipsi-, and contralateral to the injection site (Fig. 2). This is compatible with CSF-induced spreading 
of tau pathology throughout the hippocampus of inoculated mice along anatomically connected regions, 
similarly to previous findings when seeding with tau containing brain homogenates [1, 8, 33]. 
Previous seedings with brain homogenates in P301S mice resulted in a prominent increase in dot-like 
structures, attributable to axonal tau aggregates [1]. Hippocampal tissue from AD CSF seeded mice showed 
similar wide-spread dot-like structures, when stained for AT8 or AT100. Dot-like structures were most 
prominent in the dentate gyrus (DG) (Fig. 3a-f, Suppl. Figure 4a-d), as well as in the pathways of the fimbria 
(Fig. 3g-l). In CTR CSF seeded mice, some dot-like structures were also present, most prominently in the DG 
(Fig. 3a, d), and accentuated in the dorsal hippocampus, where they occur regularly in untreated aged P301S 
mice. When comparing CTR CSF to AD CSF inoculated mice, the increase in AT8 and AT100 positive dot-
like structures in the DG was significant ipsilateral to the injection site (AT8: 1,265/3,045, p=0,013 (Fig. 3a-
c); AT100: 1,930/6,400, p=0,036 (Fig. 3d-f)), and even contra-lateral to the injection site (AT8: 1,012/2,574, 
p=0,031; AT100: 3,121/6,266, p=0,047). Compatible with an induced spreading of tau aggregation, an increase 
of tau hyperphosphorylation was also noted in the fimbria, both for AT8 and AT100 positive granular 
structures (AT8: 1,736/4,310, p=0,039 (Fig. 3g-i); AT100: 2,539/5,514, p=0,018 (Fig 3j-l)), while showing a 
similar trend on the contra-lateral side (AT8: 1,603/3,258, p=0,121; AT100: 2,598/4,302, p=0,053). 
Furthermore, Gallyas-Braak staining showed an increase in silver positive hippocampal neuronal inclusions in 
AD CSF seeded host mice, both ipsilateral (Fig. 4a-c, 0,029/0,151, p=0,0007), as well as contralateral to the 




hyperphosphorylation and tau aggregation by the AD CSF tau seeds, as also visible on higher magnification 
views of the CA1 region (Fig. 4d, e). Only in a subset of mice, focal granular aggregates of Gallyas-Braak 
positive tau structures became visible. In a mouse seeded with CSF collected from patient #2, we noted a focal 
induction of Gallyas-Braak positive grains in the ipsilateral alveus above the CA1 field (Fig 4f), while in a 
mouse inoculated with CSF derived from patient #1, prominently focal granular tau structures appeared in the 
dorsal fornix, strictly limited to the inoculated side (Fig 4g). The latter finding was reminiscent of previous 
observations of focal tau aggregation in the dorsal fornix following injection of human brain extracts derived 







Here we demonstrate the in vivo tau seeding effects of cerebrospinal fluid (CSF) derived from patients 
suffering from AD dementia or mild cognitive impairment (MCI) likely due to AD. CSF containing 
hyperphosphorylated tau species accelerated tau pathology after intrahippocampal inoculation into P301S tau 
transgenic host mice. These findings corroborate two recent reports of in vitro seeding-like activity of CSF tau 
[31, 38], providing now first evidence for biological seeding activity of patients’ derived CSF tau in susceptible 
host mice.  
CSF collected from patients with a high probability of AD or related MCI was used, and compared with CSF 
derived from age-matched patients with diagnosis other than AD. Inoculation of CSF collected from AD and 
MCI patients resulted in a significant increase of markers of tau pathology in the hippocampus of P301S tau 
host mice. Advanced tau pathology was also notable in the contralateral hippocampus, and in anterior and 
posterior directions. This is comparable to the spreading we and others have described after seeding with brain 
extracts of tau transgenic mice or tauopathy patients [1, 5, 8, 9, 22].  
Besides an overall increase in tau inclusion positive hippocampal neurons, injection of concentrated AD 
patients’ CSF into young P301S tau mice resulted in focal granular, dot-like tau accumulation particularly in 
the fimbria and the dentate gyrus (DG) in a subset of the inoculated mice. This granular pathology is very 
similar to earlier findings in tau transgenic mice seeded with brain extracts from a patient who suffered from 
corticobasal degeneration [5]. Punctate Gallyas-Braak silver staining positive structures indicative of axonal 
tau aggregates accumulated in the alveus and the dorsal fornix close to the injection site in two AD CSF 
inoculated mice, reminiscent of a similar pathology induced in the fornix of P301S tau mice seeded with P301S 
tau mouse donor brain extracts [1]. These characteristic focal Gallyas-Braak positive, axonal dot-like structures 
were visible in a subset of AD CSF inoculated host mice. Seeding patterns might differ due to varieties in the 
tau strains involved in the donor patients. It has been shown that brain samples from different tauopathy 
patients may accelerate tau aggregation variably in different structures or cell types, and also propagate in 
distinctive ways, indicating the presence of different tau strains [5]. Recently, different ultrastructural 




Our findings suggest that in AD patients, pathological tau species with biological seeding competence drain 
from the brain interstitial fluid to the CSF compartment. There, they retain their potential to evoke seed-like 
effects in vivo, similarly as previously reported for brain parenchymal tau species.  
The here observed tau seeding competence of AD patients’ CSF contrasts our earlier findings in seeding 
experiments with A. There, even very long seeding times after inoculation of concentrated human or murine 
A comprising CSF into APP transgenic host mice failed to provide evidence for the presence of bioactive A 
seeds in the CSF compartment [16, 35]. The here described biological tau seeding activity of CSF is however 
not entirely surprising. In contrast to A that aggregates broadly in the brain parenchyma and the perivascular 
space, tau is readily drained towards the CSF compartment. Opposite to A, tau levels increase in the CSF 
with the progression of AD [28].  
Furthermore, our evidence for in vivo seeding activity of CSF tau follows recent findings on the ability of CSF 
tau to induce seeding-like conformational changes in vitro [31, 38]. Ventricular CSF samples collected post 
mortem at autopsies of AD patients have been inducing tau aggregation in HEK293 cells expressing a P301S 
tau repeat domain [38]. CSF tau derived from Pick’s disease patients has furthermore been found to induce 
real-time quaking conversion (RT-QuIC) of a 3 repeat tau fragment [31]. In vitro seeding activity in cellular 
systems, or prion-like substrate conversion capacity by RT-QuIC, has furthermore recently been demonstrated 
for CSF in the context of other neurodegenerative proteinopathies, including sporadic Creutzfeldt Jakob 
disease [15] and Huntington’s disease [39]. 
The presence of bioactive tau seeds in the CSF of AD patients suggests a diagnostic use of the aggregation 
induction capacity of CSF in tauopathies. In contrast to brain tissue, CSF can easily be collected from patients 
with a low rate of side effects [30]. The simple analysis of CSF tau levels is an established part of the diagnostic 
criteria for AD, but it lacks yet high specificity and is unable to provide prognosis at early or even preclinical 
disease stages [11, 28]. The latter would however be important also for the development of novel therapies. 
Our detection of bioactive tau seeds in CSF of AD patients augurs well for the development of novel diagnostic 
tools that are based on the specific conformational properties and the bioactivity of tau.  
The biological in vivo seeding capacity of AD patients’ CSF that we describe calls for considerations on the 
biosafety of operators when handling CSF samples. Compared to previous seedings with brain tissues [8], the 




system are relatively mild. We therefore consider the seeding potential of AD tau in CSF rather low. We 
however did not compare the seeding capacity of AD CSF to proportionately diluted AD brain lysates, so that 
a direct comparison of the seeding potential of CSF to brain-derived tau remains yet to be done. The host mice 
used in the present study furthermore express a human P301S mutant tau form which is particularly prone to 
aggregation. The present findings therefore can’t be directly translated into the setting where people with 
normal wild-type tau would be exposed to AD patients’ tau samples. Altogether, the seeding potential of CSF 
might be of limited relevance in a routine laboratory or clinical setting when adhering to standard safety 
procedures for the handling of potentially infectious bio-samples. 
This study is subject to some limitations. Due to the large amounts of CSF needed, CSF had to be collected 
consecutively from donating patients. This resulted in a limited number of patients’ samples attributable to 
either the AD- or the control-group, similar to the previous in vitro study done in HEK293 cells [38]. As tau 
seeding is a time and concentration dependent process [9], we concentrated the CSF samples before the 
intracerebral inoculations. We can’t therefore exclude, that the seeding potential of tau was increased by the 
concentration process itself. The absence of any seeding activity in our previous experiments with concentrated 
CSF-A [16, 35], as well as the significant differences between the CSF tau derived from AD patients versus 
the controls, however speak against a relevant influence of the concentrating procedure. Given the short life 
span of homozygous P301S tau mice, the maximum seeding time was limited to 4 months. We therefore can’t 
exclude that a more robust seeding response would become apparent at later time points post-seeding.  
The exact nature of bioactive tau seeds has yet remained unknown. The need of large amounts of CSF for 
seedings in the present study has precluded any detailed analysis of the bioactive seeds. In their post mortal 
CSF samples, Takeda et al. found high molecular weight tau (HMW) species, and considered them to be the 
bioactive species in vitro [38]. Future studies will be needed to analyze the structural nature of CSF tau 
bioseeds.  
In conclusion, we here provide first in vivo evidence for the presence of bioactive tau aggregation accelerating 
seeds in CSF of AD patients. Further studies will be needed to elaborate whether CSF derived bioactive tau 
seeds might be of use as a marker of AD, as well as to study mechanistic aspects of potentially strain specific 
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clinical data 
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Table.1: Clinical, imaging, and laboratory findings of the patients selected for the preparation of CSF seeds 
(CTR CSF: control patients’ group, AD CSF: Alzheimer’s disease group). Bold letters indicate pathological 
values of CSF tau, p-tau or A. NIA-AA criteria: National Institute on Aging-Alzheimer's Association 
workgroups on diagnostic guidelines for Alzheimer's disease. Criteria abbreviation: BP = “Biomarker 









Fig.1: Immunohistochemistry for AT8 and AT100 tau phosphorylation markers of 7 months old P301S 
transgenic mice, sacrificed 4 months after unilateral hippocampal inoculation with CSF derived from control 
patients (CTR) or AD patients (AD) (a, d; b, e). AT8 positive hippocampal neurons (c, p=0,001) ipsilateral to 
the inoculation site; AT100 positive hippocampal neurons, ipsilateral (f, p=0,0013). Scale bar in e equals 500 
















Fig.2: Heat map of a semiquantitative analysis of AT8 tau positive neurons anterior and posterior, as well as 
ipsilateral (asterisks) and contralateral to the injection site after CTR CSF and AD CSF seedings. Bregma 
levels 2-2.5/2-2.5 mm (a, c, anterior), and 2.5-3/2.5-3 mm (b, d, posterior).  
Figure 3 
 
Fig.3: AT8 and AT100 immunohistochemistry after unilateral hippocampal seeding with CTR CSF (a, g ; d, 
j) and AD CSF (b, h; e, k) into P301S mice. Accumulation of AT8 (c, p=0.013) and AT 100 (f, p=0.036) 
positive dot-like structures in the DG ipsilateral to the injection site. Increase in AT8 (i, p=0.039) and AT 100 
(l, p=0.018) positive dot-like structures in the fimbria. Scale bar in e equals 150 m in a, b, d and e; scale bar 







Fig.4: Gallyas-Braak stainings. Overview on the hippocampus (CTR CSF: a, AD CSF: b). Increase in Gallyas-
Braak positive hippocampal neurons in AD CSF seeded mice compared to CTR CSF seedings (c, p=0.0007). 
Gallyas positive neurons in the CA1 subfield (CTR CSF: d, AD CSF: e). Focal dot-like Gallyas-Braak positive 
structures in the ipsilateral alveus above the CA1 field after inoculation of CSF from patient #2 (f, arrow), and 
in the ipsilateral dorsal fornix after seeding with CSF from patient #1 (g). Scale bar in a equals 500 m in a 























Suppl. Figure 1:  
CSF was collected from patients and controls by a lumbar puncture, obtaining about 10ml on 
average. From those, 8ml were used for subsequent lyophilization, dialysis, and re-lyophilization, 
and finally dissolved in 66μl sterile water, with a theoretical concentration factor of 120x. 
 
Suppl. Figure 2: CSF tau concentrations 
 
Suppl. Figure 2: Tau and phospho-tau (P-Tau, T231) concentration of the patients CSF used for 
seeding experiments, as measured by ELISA. There was no significant difference of the total tau 
levels between the AD and the CTR group, as measured by ELISA, before (0,530 ng/ml / 0,307 






Suppl. Figure 3: CA1 pathology 
 
Suppl. Figure 3: Immunohistochemistry of the hippocampal CA1 field for AT8 and AT100 tau 
phosphorylation markers of 7 months old P301S transgenic mice, sacrificed 4 months after 
unilateral hippocampal inoculation with CSF derived from control patients (CTR) or AD patients 
(AD) (a-d). Scale bar in d equals 100 m and applies to a-d. 
Suppl. Figure 4: DG pathology 
 
Suppl. Figure 4: Immunohistochemistry of the dentate gyrus for AT8 and AT100 tau 
phosphorylation markers of 7 months old P301S transgenic mice, sacrificed 4 months after 
unilateral hippocampal inoculation with CSF derived from control patients (CTR) or AD patients 





Supplemental Table:  
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(AD/CTR) 























































P value IPSI 
(AD vs CTR) 
0,001 0,013 0,0007 0,013 0,036 0,942 0,039 0,018 0,218 
P value 
CONTRA 
(AD vs CTR) 
0,053 0,053 0,014 0,031 0,047 0,884 0,121 0,053 0,309 
 
Suppl. Table 1: Overview of the statistical data of unilateral intrahippocampal seedings with CSF 
derived from AD patients (AD) and control patients (CTR) into P301S mice. Abbreviations: HIPP: 
Hippocampal, DG: dentate gyrus, IPSI: ipsilateral to the intrahippocampal inoculation of the seed, 
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Tau is a microtubule stabilizing protein that forms abnormal aggregates in many neurodegenerative disorders, 
including Alzheimer’s disease. We have previously shown that co-expression of fragmented and full-length 
tau in P301SxTAU62on tau transgenic mice results in the formation of oligomeric tau species and causes severe 
paralysis. This paralysis is fully reversible once expression of the tau fragment is halted, even though P301S 
tau expression is maintained. Whereas various strategies to target tau aggregation have been developed, little 
is known about the long-term consequences of reverted tau toxicity.  
Therefore, we studied the long-term motor fitness of recovered, formerly paralyzed P301SxTAU62on-off mice. 
To further assess the seeding competence of oligomeric toxic tau species, we also inoculated ALZ17 mice with 
brainstem homogenates from paralyzed P301SxTAU62on mice.  
Counterintuitively, after recovery from paralysis due to oligomeric tau species expression, aging 
P301SxTAU62on-off mice did not develop more motor impairment or tau pathology when compared to 
heterozygous P301S tau transgenic littermates. Thus, toxic tau species causing extensive neuronal dysfunction 
can be cleared without inducing seeding effects. Moreover, these toxic tau species also lack long-term tau 
seeding effects upon intrahippocampal inoculation into ALZ17 mice.  
In conclusion, tau species can be neurotoxic in the absence of seeding-competent tau aggregates, and mice can 
clear these tau forms permanently without tau seeding or spreading effects. These observations suggest that 
early targeting of non-fibrillar tau species may represent a therapeutically effective intervention in tauopathies. 
On the other hand, the absent seeding competence of early toxic tau species also warrants caution when using 
seeding-based tests for preclinical tauopathy diagnostics.  
 
 








AD: Alzheimer’s disease 
NFT: Neurofibrillary tangles 
H&E: Hematoxylin and eosin 
HRP: Horseradish peroxidase 
ANOVA: Analysis of variance 
AgD: Argyrophilic grain disease 
PSP: Progressive supranuclear palsy 
















Tau is a soluble protein acting as a microtubule stabilizer in neuronal cells. Under pathological conditions it 
becomes hyperphosphorylated and eventually forms intracellular aggregates. Tau aggregates are a hallmark of 
Alzheimer’s disease (AD) and other neurodegenerative disorders, including forms of frontotemporal dementia 
(Spillantini and Goedert, 2013; Spires-Jones and Hyman, 2014). The mechanisms underlying pathological tau 
aggregation remain only partly understood. Tau is thought to aggregate through the formation of oligomeric 
species and subsequent aggregation into fibrils, culminating in the formation of tangles. Tau aggregation can 
spread towards anatomically connected regions in a prion-like manner (Clavaguera et al., 2009; Goedert et al., 
2017).  
We have recently shown that tau toxicity can be mediated by oligomeric tau species (Ozcelik et al., 2016). Co-
expression of full-length P301S mutant tau with a 3R tau151-421 fragment (tau151-421) in 3-weeks-old 
P301SxTAU62on transgenic mice leads to the formation of soluble high molecular weight tau oligomers. In the 
P301SxTAU62on mouse model, high molecular weight tau oligomers are sufficient to cause extensive nerve 
cell dysfunction and severe motor palsy, both of which occur in the absence of insoluble tau aggregates or 
neurofibrillary tangles (NFTs) (Ozcelik et al., 2016). Strikingly, once the doxycycline-inducible expression of 
tau151-421 is switched off in these mice, their severe phenotype reverses within 3 weeks, and animals regain 
their motor competence, even though heterozygous P301S mutant tau expression is maintained (Ozcelik et al., 
2016). This phenotype reversibility renders P301SxTAU62on-off mice suitable for investigating potential long-
term consequences of reverted tau toxicity. The relevance of oligomeric tau toxicity is being increasingly 
recognized, and recent studies have shown that it can also be pharmacologically attenuated (Bittar et al., 2019; 
Lo et al., 2019; Abskharon et al., 2020; Lo Cascio et al., 2020; Puangmalai et al., 2020). Hypothesized to 
depend on oligomer conformation, tau oligomeric toxicity can also be aggravated by biological interactions 
with chaperones (Oroz et al., 2018), RNA-binding proteins (Jiang et al., 2019), and nuclear complexes 
(Eftekharzadeh et al., 2018). Due to their interaction with cellular components and their importance in tau 
propagation, tau oligomers have been considered crucial for tau-mediated neurodegeneration. 
Long-term effects after recovery from oligomeric, non-fibrillar tau toxicity have not yet been assessed. Here, 




pathology have been widely studied in human tauopathies as well as in tau transgenic mouse models (Maeda 
et al., 2007; Clavaguera et al., 2009; Sanders et al., 2014; Mudher et al., 2017). Based on this accumulated 
evidence, we hypothesized that the tau oligomers abundantly present in young paralyzed P301SxTAU62on 
mice might act as seed for tau accumulation, as P301S full-length tau expression is maintained, while 
doxycycline-driven tau151-421 expression is switched off. To our surprise, P301SxTAU62
on-off mice that had 
recovered from neurotoxic stress and motor palsy did not develop worse motor function nor more pronounced 
tau pathology during aging when compared to their P301S tau heterozygous littermates. This demonstrates 
that P301SxTAU62on-off mice clear their toxic tau aggregates without seeding NFT formation, and hence do 
not show pronounced motor decline upon aging. 
To study whether the toxic tau species causing palsy in young P301SxTAU62on mice also lack classical seeding 
competence, we next stereotactically inoculated brainstem homogenates of paralyzed P301SxTAU62on into 
ALZ17 human wild-type tau transgenic mice. In contrast to ALZ17 mice seeded with P301S brainstem 
homogenates containing fibrillary tau species (Clavaguera et al., 2009), ALZ17 mice inoculated with 
P301SxTAU62on homogenate did not develop fibrillar tau pathology, arguing against a seeding competence of 
the early toxic tau forms in P301SxTAU62on mice. 
Lacking seeding competence of non-fibrillar toxic tau species as well as absent long-term sequelae after halting 
their expression warrants the exploration of early therapeutic interventions targeting pre-fibrillar tau species. 









Transgenic homozygous mice expressing human ALZ17 mutant tau (ALZ17 mice) (Probst et al., 2000), 
transgenic homozygous mice expressing human P301S mutant tau (P301S mice) (Allen et al., 2002), 
transgenic heterozygous mice expressing human Δtau151-421 (TAU62 mice) (Ozcelik et al., 2016), and non-
transgenic C57BL/6J (BL6 mice) control mice were used. P301S mice and TAU62 mice were interbred to 
obtain double transgenic P301SxTAU62 mice (Ozcelik et al., 2016). All animal experiments were performed 
in compliance with protocols approved by the Committee for Animal Care and Animal Use of the Canton of 
Basel (Licenses Nr. BS 2364 and 2471). 
Behavioral tests 
Motor behavior, including gait ataxia, tremor, and hindlimb reflexes was assessed. Quantitative motor testing 
was performed by the grid test in which mice were placed on a vertical mesh grid and the latency to fall off 
the grid was recorded for 3 min. Motor coordination and balance were assessed using the Panlab Harvard 
Rotarod (Harvard Apparatus, Holliston, USA). The rotarod starts at a speed of 4 rpm and accelerates by 1 rpm 
every 3 sec. In both, grid test and rotarod assay, mice were tested for 3 consecutive days with 3 trials per day, 
with minimum rest intervals of 5 min, and the mean latency to fall was documented. Results were obtained by 
averaging the daily means of 3 consecutive days. 
Stereotactic surgery 
For surgery, 3-months-old ALZ17 mice were anesthetized with a mixture of ketamine (10 mg/kg) and xylazine 
(20 mg/kg) and placed on a heating pad to maintain body temperature. Mice were stereotactically injected into 
the right hippocampus (A/P, −2.5 mm from bregma; L, − 2.0 mm; D/V, −1.8 mm) using a Hamilton syringe. 
Brainstem homogenates of 6-months-old paralyzed homozygous P301S mice and 3-weeks-old paralyzed 
P301SxTAU62on mice were prepared for inoculation in ALZ17 mice. Brainstems were weighted and diluted 
1:10 in PBS for seeding. After dilution, samples were homogenized using an Ultraturrax T8 (IKA 
Labortechnik, Staufen im Breisgau, Germany) and sonicated briefly (Bandelin SONOPULS, Bandelin, Berlin, 




at 4 °C, and aliquots of the supernatant were stored at -70 °C for later usage. During inoculation, each mouse 
received 5 μl of brainstem homogenate at a speed of 1.25 μl/min. Following injection, the needle was kept in 
place for additional 3 minutes before withdrawal. The surgical area was cleaned with sterile saline and the 
incision sutured. Mice were monitored until recovery from anaesthesia, post-interventional analgesia was 
administered, and animals were checked regularly following surgery. After 20 months of incubation, the 
seeded mice were sacrificed. 
Immunohistochemistry 
Mice were deeply anesthetized with pentobarbital and transcardially perfused with 20 ml cold PBS, followed 
by 20 ml 4% paraformaldehyde in PBS. The brains were dissected and post-fixed overnight. Following paraffin 
embedding, 4 μm coronal sections were cut from the brains of seeded mice, whereas 4 μm sagittal sections 
were prepared from the brains of mice used for the behavioral tests. Sections were silver-impregnated 
following the method of Gallyas-Braak to visualize filamentous tau pathology. Hematoxylin and eosin staining 
(H&E) was performed for morphological analysis. For immunohistochemistry, the following anti-tau 
antibodies were used: AT8 (1:1000, Pierce Biotechnology, Waltham, USA), AT100 (1:1000, Pierce 
Biotechnology, Waltham, USA), TauC3 (1:1000, Santa Cruz Biotechnology, Santa Cruz, USA). Secondary 
antibodies were from Vector Laboratories, Burlingame, USA (Vectastain ABC kit). 10X, 20X and 40X 
magnified pictures of the stained slides were taken with an Olympus BX43 Upright Microscope (Life Sciences 
Solutions, Chicago, USA). 
Western blots 
For the western blots comparing total and soluble tau in 16-months-old P301S heterozygous (P301Shet) and 
P301SxTAU62on-off mice, brains were homogenized in cold extraction buffer 20 % (w/v) (25 mM Tris-HCl pH 
7.4, 150 mM NaCl, 1mM EDTA, 1mM EGTA, 5 mM NaPyrophosphate, 10 mM B Glycerophosphate, 30 mM 
NaFluoride, 10 mM NaVanadate, with addition of 100 ul/10 ml PMSF of 0.1 M just before use, and 1 Pierce 
protease and phosphatase inhibitor mini tablet, EDTA-free, Pierce Biotechnology, Waltham, USA) using a 
Polytron Homogenizer (Thomas Scientific). An aliquot of the resulting homogenate was collected as total tau. 
Subsequently, samples were centrifuged at 80000 g for 15 min using an ultracentrifuge (Beckman Coulter, 




For the western blot comparing total tau in 3-months-old mice, one half of the mouse brain was dissected into 
forebrain and brainstem, and frozen in liquid nitrogen or on dry ice. Brainstems were weighted and diluted 
1:10 in TBS-Complete. Subsequently, samples were homogenized using an Ultraturrax T8 (IKA Labortechnik, 
Staufen im Breisgau, Germany) and briefly sonicated (Bandelin SONOPULS, Bandelin, Berlin, Germany; 
90% power, 10% cycle, 10 sec pulses). Homogenates were then centrifuged at 4000 g for 20 minutes at 4 °C, 
and aliquots of the supernatant stored at -70 °C for later usage. Western blots were then performed under non-
reducing conditions using appropriate amounts of protein, 4X NuPAGE LDS sample buffer, and deionized 
water. 10X NuPAGE reducing agent was used to obtain reducing conditions. Following appropriate 
preparation, samples were loaded onto a 7% NuPAGE® Tris-acetate gel. After the removal of gels from the 
cassette and activation of PVDF membrane (Amersham Biosciences, Amersham, UK) samples were 
transferred on the PVDF membrane using the XCell IITM Blot Module. Unspecific binding epitopes were 
blocked with 5% non-fat milk in PBS-Tween, followed by incubation with primary antibody over night at 4 
°C on a shaker. After washing with PBS-Tween, the membrane was incubated with horseradish peroxidase 
(HRP)-conjugated anti-mouse or -rabbit secondary antibody at room temperature. Then, the membrane was 
washed again in PBS-Tween and detected by electrochemiluminescence (ECL) (GE Healthcare, Little 
Chalfont, UK). The anti-tau antibody used for the western blots was HT7 (1:1000, Pierce Biotechnology, 
Waltham, USA). 
Sarkosyl extraction and immunoelectron microscopy 
Following PBS perfusion, mouse brainstem tissue was dissected and frozen in liquid nitrogen. Sarkosyl 
extraction was performed as described (Delobel et al., 2008). Briefly, the brainstem tissue was homogenized 
in A68 buffer (0.5 ml of 800 mM NaCl, 10% sucrose, 10 mM Tris-HCl pH 7.4, 1mM EGTA) using a Kinetica 
polytron. Samples were centrifuged at 5,000g for 15 min. The collected supernatant was analysed as total tau 
samples. Following sarkosyl addition to 1% and shaking for 1 h, samples were centrifuged at 80,000g for 30 
min. The resulting pellet was resuspended in 50mM Tris-HCl pH 7.4.  
For immunoelectron microscopy, aliquots were placed on carbon-coated 400 mesh grids and allowed to dry 
partially. Grids were blocked in droplets of 0.1% gelatin (Sigma G7041, Sigma-Aldrich, St. Louis, MO, USA) 




with blocking buffer, stained with anti-mouse IgG-Gold secondary antibody (Sigma G7652), washed with 
water, and stained with 2% uranyl acetate. Electron microscopy was performed using a FEI Tecnai Spirit TEM 
at a magnification of 21,000x and images recorded using a Gatan Orius SC200B CCD camera (Gatan, 
Pleasanton, CA, USA). 
Dot blots 
For dot blots, serum of 3-months-old P301Shet and P301SxTAU62on-off mice was separated from the clot by 
centrifuging the samples at 1000 rpm for 15 minutes at 4 °C, with the remaining supernatant aliquoted and 
stored at -20 °C, for later usage. Then, a nitrocellulose membrane (Bio-Rad Laboratories, Inc., Hercules, USA) 
was divided in a grid to allow later incubations with 3-months-old P301Shet and P301SxTAU62on-off sera and 
HT7 antibody as positive control at 1:1000 dilutions. 0.2 mg/ml of 2N4R wild-type tau monomers were applied 
on a 4x3 grid. Next, unspecific binding epitopes were blocked with 5% BSA in PBS-Tween, followed by a 30-
minutes-long incubation at room temperature with previously extracted sera from the mice and HT7 antibody 
as positive control. After washing with PBS-Tween, the membrane was incubated with HRP-conjugated anti-
mouse secondary antibody at room temperature, washed again in PBS-Tween, and detected by ECL (GE 
Healthcare, Little Chalfont, UK). 
Statistical analysis 
To evaluate behavioral test results statistically, one-way analysis of variance (ANOVA) followed by post-hoc 
Student’s t-tests and Bonferroni correction for multiple comparisons were applied. P-values < 0.05 were 
considered significant. To estimate soluble tau and total tau expression from western blots of 3-months-old 
and 16-months-old mice, the protein bands were normalized to GAPDH protein standard, and quantified using 
ImageJ software; generated mean ratio values were compared by Student’s t-test. To determine the effect of 
early neurotoxic stress in aged mice, AT8 and Gallyas-positive neurons were semi-quantitatively assessed in 
brainstem regions. Three sections per animal were analysed. The total area analysed per animal was 
comparable between animals (AT8: P-value = 0,34, and Gallyas: P-value = 0,91). P-values calculated by 
Student’s t-tests were interpreted exploratory and not adjusted for multiple comparisons; P-values < 0.05 were 
considered significant. Box plots for figures 2 to 5 were generated with R software. The lower and upper hinges 




hinge to the largest value no further than 1.5 times IQR from the hinge (where IQR is the inter-quartile range, 
or distance between the first and third quartiles). The lower whisker extends from the hinge to the smallest 
value at most 1.5 times IQR of the hinge. Data beyond the end of the whiskers are called "outlying" points and 
are plotted individually. 
Availability of data and materials 







Co-expression of tau fragment and full-length tau induces severe reversible neurotoxicity in 
P301SxTAU62on mice in the absence of tau fibrils 
P301SxTAU62on transgenic mice co-expressing human Δtau151-421 with full-length P301S mutant tau were 
obtained by interbreeding P301S tau transgenic mice with TAU62 transgenic mice, where Δtau151-421 
expression is regulated by a doxycycline-responsive promoter element (Ozcelik et al., 2016). 3-weeks-old 
heterozygous P301S transgenic littermates (P301Shet) did not exhibit signs of motor dysfunction, as also 
illustrated by their normal tail suspension test (Fig. 1A). In contrast, P301SxTAU62on mice of the same age 
showed a severe hindlimb palsy, only being able to move by the use of their forelimbs (Fig. 1B). Upon halting 
doxycycline administration to stop Δtau151-421 expression, this phenotype was fully reversible within three 
weeks, even though P301S tau expression continued (Fig. 1C).  
Histological examination did not reveal any tau pathology in young P301Shet mice (Fig. 1A). In contrast, 
extensive AT8-positive pre-tangle stage tau pathology was found in paralyzed, 3-weeks-old P301SxTAU62on 
mice (Fig. 1B). Remarkably, three weeks after Δtau151-421 expression had been stopped, AT8-positive tau 
pathology was no longer detectable, and by the age of six weeks, P301SxTAU62on-off mice had regained normal 
walking capability (Fig. 1C). Gallyas-Braak silver stain positive tau pathology was absent in 3-weeks-old 
P301Shet mice (Fig. 1A), their paralyzed P301SxTAU62on littermates (Fig. 1B), as well as in recovered 
P301SxTAU62on-off mice (Fig. 1C, for high magnification pictures see Supplementary Fig. 1).  
Immunoelectron microscopy confirmed the absence of tau filaments in brainstem samples of paralyzed 
P301SxTAU62on mice (Fig. 2). Total tau as well as sarkosyl extracts of brainstem homogenates collected from 
6-months-old homozygous P301S tau transgenic mice showed HT7-positive tau filaments (Fig. 2A). In 
contrast, only oligomeric, non-fibrillar tau structures were detectable in total tau extracts of 3-weeks-old 
paralyzed P301SxTAU62on mice, and no aggregated tau structures could be found in sarkosyl extracts from 
paralyzed P301SxTAU62on mice (Fig. 2B). Extracts from non-transgenic 3-weeks-old BL6 mice were used as 
negative controls (Fig. 2C). These observations demonstrate that the severe, but reversible motor palsy in 
P301SxTAU62on-off mice is mediated by non-fibrillar tau species (Ozcelik et al., 2016).  A graphical 





Absence of excessive motor impairment in aged P301SXTAU62on-off mice after recovery from early 
severe neurotoxicity 
To study the long-term effects of the severe non-fibrillar tau stress in P301SxTAU62on mice, we followed their 
motor capabilities after their initial recovery. As only Δtau151-421 expression is under the control of a 
doxycycline-responsive promoter element, recovered P301SxTAU62on-off mice maintain expression of P301S 
mutant full-length tau.  
We compared formerly paralyzed, recovered and aged P301SxTAU62on-off mice to their P301Shet littermates 
and to non-transgenic BL6 mice by tail suspension, rotarod, and grid tests at the age of 16 months. P301Shet 
littermates showed signs of hindlimb clasping, while recovered P301SxTAU62on-off mice were still able to 
spread their hindlimbs, as were non-transgenic BL6 mice (Fig. 3A).  
As expected, at 16 months of age, motor balance (rotarod) was significantly reduced in both tau expressing 
mouse models, compared to non-transgenic BL6 mice. Somewhat surprisingly, however, we did not detect a 
worse motor performance of P301SxTAU62on-off mice in comparison to their P301Shet littermates. In contrast, 
formerly paralyzed P301SxTAU62on-off mice performed even slightly better in the rotarod test when compared 
to P301Shet littermates, although this did not reach statistical significance (Fig. 3B). Similar observations were 
made for the grid test, revealing a significantly reduced motor strength in P301Shet transgenic mice in 
comparison to non-transgenic BL6 mice. Again, at the age of 16 months, P301SxTAU62on-off mice showed a 
slightly better grid test performance than their P301Shet littermates, although again without statistical 
significance (Fig. 3C, see Supplementary Table 1 for complete values). Thus, P301SxTAU62on-off mice 
recovered from early neurotoxic tau stress and did not show increased motor impairment with aging when 







Absence of excessive tau pathology in aged P301SxTAU62on-off mice after recovery from severe 
neurotoxicity 
We next aimed at studying whether the absence of a pronounced motor phenotype in P301SxTAU62on-off mice 
would also be mirrored by the extent of tau pathology upon aging. To this end, we comparatively analysed 
brains of 16-months-old P301SxTAU62on-off and P301Shet mice by histology. In all mice, tau pathology was 
most extensive in the brainstem. AT8 immunohistochemistry revealed extensive tau hyperphosphorylation in 
P301Shet mice whereas significantly less tau hyperphosphorylation was present in P301SxTAU62on-off animals 
(Fig. 4A, B, for high magnification pictures see Supplementary Fig. 3). Additional immunohistochemistry with 
the AT100 antibody revealed similar results for 16-months-old mice, confirming the significantly more 
abundant hyperphosphorylation in the heterozygous mice which did not experience the early neurotoxic stress 
as the recovered mice did (see Supplementary Fig. 4). 
Gallyas-Braak silver staining revealed widespread, robust tau tangle formation in the brainstem of P301Shet 
mice, whereas formerly paralyzed P301SxTAU62on-off mice remained almost devoid of fibrillar tau pathology 
(Fig. 4C, D, for high magnification pictures see Supplementary Fig. 3). Semiquantitative assessment confirmed 
the lower extent of tau pathology in aged P301SxTAU62on-off compared to P301Shet mice (see Supplementary 
Table 2 for complete values). Immunohistochemistry with TauC3 antibody did not reveal leakage of Δtau151-
421 expression in 16-months-old P301SxTAU62
on-off mice (Supplementary Fig. 4). A graphical representation 
of these findings can be found in Supplementary Fig. 2. 
We confirmed our histological findings by western blotting, using the human tau targeting HT7 antibody. 
Significantly higher levels of total (Fig. 5A, B) and soluble tau (Fig. 5C, D) were detected in P301Shet mice 
compared to P301SxTAU62on-off mice at 16 months of age (see Supplementary Table 2 for complete values). 
Next, we wanted to rule out that the mild motor phenotype as well as the comparatively mild tau pathology in 
aged P301SxTAU62on-off mice were caused by loss of human mutant P301S tau expression. To this end, we 
analysed tau protein levels in these mice and their heterozygous littermates at the age of 3 months. Western 
blot analysis revealed comparable total tau levels in P301Shet and P301SxTAU62on-off mice (Fig. 6A, B; see 
Supplementary Table 2 for complete values). It is therefore unlikely, that the maintained motor competence of 




paralyzed P301SxTAU62on mice. Nevertheless, based on western blotting, discretely reduced tau expression 
levels in P301SxTAU62on-off compared to P301Shet mice cannot be excluded. Therefore, a mildly lowered tau 
expression might have been contributed to the slightly better motor performance and the less extensive tau 
pathology in aged P301SxTAU62on-off mice. In light of the extensive early tau toxicity occurring in 
P301SxTAU62on mice, an immunological reaction could also have been triggered by the toxic high molecular 
weight tau, and may have caused the lower tau levels in aged P301SxTAU62on-off mice. However, dot blot 
analysis did not detect any anti-tau antibodies in sera of 3-months-old P301Shet and P301SxTAU62on-off mice 
(Supplementary Fig. 5). 
 
 
Brainstem homogenates from paralyzed P301SxTAU62on mice do not induce NFT formation in ALZ 17 
mice 
Our observations made so far argued against a long-term seeding effect of the early, non-fibrillar neurotoxic 
tau species which caused the severe motor palsy in P301SxTAU62on mice. To assess the seeding capacity of 
these non-fibrillar toxic tau species also in a classical tau seeding setting (Clavaguera et al., 2009), we next 
prepared brainstem homogenates from paralyzed 3-weeks-old P301SxTAU62on mice, and inoculated them 
intrahippocampally into 3-months-old ALZ17 tau transgenic mice. Brain homogenates derived from aged 
tangle-bearing homozygous P301S tau transgenic mice were used as positive controls, as these had previously 
been proven to provoke the formation of Gallyas-Braak silver stain-positive tangles when inoculated into 
ALZ17 mice (Clavaguera et al., 2009). As expected, ALZ17 mice seeded with P301S brainstem homogenates 
developed granular focal tau pathology, primarily in CA1 (Fig. 7A) and the ipsilateral dorsal fornix above CA1 
(Fig. 7B). In contrast, ALZ17 mice seeded with P301SxTAU62on brainstem homogenates remained devoid of 
Gallyas-Braak silver stain positive structures up to the age of 20 months. This observation indicates that the 
non-fibrillar toxic tau species associated with the severe paralysis of P301SxTAU62on mice are not seeding-






We here report that early neurotoxic tau stress causing severe motor paralysis in P301SxTAU62on mice is fully 
reversible and does not cause late seeding or adverse effects in recovered P301SxTAU62on-off mice during 
aging. Furthermore, we find that the inoculation of brainstem homogenates from paralyzed P301SxTAU62on 
mice into ALZ17 mice does not result in tau seeding in the host mice, demonstrating that non-fibrillar 
neurotoxic tau species can lack classical seeding competence.  
Co-expression of a tau151-421 with full-length P301S mutant tau in P301SxTAU62
on mice causes severe 
paralysis after three weeks, as we have previously reported (Ozcelik et al., 2016). This motor impairment is 
paralleled by an increase in hyperphosphorylated tau, but occurs in the absence of fibrillar tau forms or tau 
tangles. Upon switching off tau151-421 expression, hyperphosphorylated tau species are no longer detectable 
and P301SxTAU62on-off mice regain their motor function. This confirms that hyperphosphorylated non-fibrillar 
tau oligomers can mediate early neurotoxicity, and that clearance of these tau species rescues the paralyzed 
mice from their motor impairment (Ozcelik et al., 2016).  
While over-expression of non-aggregating tau deletion mutants lacks relevant neurotoxicity (Macdonald et al., 
2019), we here confirm that soluble oligomeric, yet non-fibrillar tau aggregates can exert extensive tau toxicity. 
This is also in line with reported clinical data: tau oligomers appear early in the brains of patients developing 
AD (Patterson et al., 2011; Lasagna-Reeves et al., 2012; Koss et al., 2016) and progressive supranuclear palsy 
(Gerson et al., 2014), possibly even before first clinical symptoms become apparent (Maeda et al., 2006). Tau 
oligomers have also been shown to correlate well with neurodegeneration in tau transgenic mice (Gomez-Isla 
et al., 1997; Lasagna-Reeves et al., 2011; Jiang et al., 2019). Based on this, oligomeric tau species are now 
considered to play a central role in the pathogenesis of neuronal dysfunction in tauopathies (Ghag et al., 2018; 
Polanco et al., 2018; Sengupta et al., 2018; Bittar et al., 2019), comparably to oligomeric structures in other 
neurodegenerative disorders (Hong et al., 2018; Sekiya et al., 2019). The severe early neurotoxic stress 
provoked by non-fibrillar tau forms in our P301SxTAU62on-off mice strengthens this view.  
Counterintuitively, we here find that P301SxTAU62on-off mice, which have been exposed to non-fibrillar 
neurotoxic tau, do not show an accelerated course of their tauopathy during aging. In contrast, aged 




heterozygous P301S littermates, even though P301S tau expression remains unaffected upon switching off 
tau151-421 expression. To our knowledge, this is the first analysis of long-term consequences of early tau stress 
in a model maintaining the expression of an aggregation-prone tau form. Previous studies were conducted in 
mouse models conditionally expressing a single mutant human tau form, and the recovery of these mice was 
achieved by its suppression (Van der Jeugd et al., 2012; Polydoro et al., 2013; Wang et al., 2018). Thus, upon 
switch-off, aggregation-prone human tau forms were no longer expressed in these mice – a scenario, which 
does not reflect the situation of potential interventional tau clearance in humans. In addition, previous studies 
in rTgTauEC mice have shown that NFT-associated toxicity can be reversed by suppressing tau overexpression 
(Polydoro et al., 2013). In pro-aggregant hTau40 transgenic mice, motor fitness improved after stopping 
mutant tau expression (Van der Jeugd et al., 2012). Similar results were obtained in PS19 mice by antisense 
oligonucleotide-mediated downregulation of mutant tau expression (DeVos et al., 2013; DeVos et al., 2017). 
Whereas our previous studies showed that tau oligomeric stress can result in severe motor impairment in the 
absence of tau fibrils (Ozcelik et al, 2016), our present findings now further separate tau toxicity from tangle 
formation by providing first evidence that early tau toxicity can be reverted even without subsequent seeding 
of fibrillar tau tangles. This indicates that halting tau oligomer-related toxicity prior to the appearance of 
filamentous tau can not only reverse clinical symptoms (as reflected by the motor phenotype recovery of our 
mice), but may also efficiently prevent long-term tau seeding and spreading. Strikingly, interventions with 
compounds targeting tau oligomers have already shown beneficial effects, including the reversal of brain 
dysfunction (Castillo-Carranza et al., 2014; Soeda et al., 2015; Gerson et al., 2018; Lo Cascio et al., 2019; Lo 
et al., 2019). Our new findings suggest that early therapeutic tau oligomer removal might efficiently prevent 
the progression of tauopathies.  
We cannot exclude that the lack of a late tau seeding effect by early toxic tau species in aging P301SxTAU62on-
off mice is caused by immunological reactions targeting tau in these mice. The slower decline of motor function 
of recovered, aging P301SxTAU62on-off mice could also be associated with a protective mechanism triggered 
by the early neurotoxic tau stress. While a dot blot analysis of sera of P301SxTAU62on-off mice did not reveal 
any antibodies targeting recombinant tau, this does not fully rule out alternative immunological mechanisms 
(e.g. T-cell mediated; antibodies against specific epitopes of oligomeric tau assemblies). Furthermore, the 




induction by the early oligomeric tau stress that these mice experienced; in support of the latter notion, it was 
previously found that pharmacological autophagy activation can defer tau pathology progression in P301S 
mice (Schaeffer et al., 2012; Ozcelik et al., 2013). 
As we cannot exclude that the lack of a late tau seeding effect by early toxic tau species in P301SxTAU62on-
off mice is attributable to immunological reactions or the induction of the autophagy pathway targeting 
oligomeric tau in these mice, we next investigated whether the early toxic tau species exert classical prion-like 
seeding competence upon intracerebral inoculation. Fibrillar tau induces the aggregation of soluble tau species 
in a prion-like manner upon inoculation into tau transgenic host mice (Clavaguera et al., 2009; Goedert et al., 
2017). We inoculated ALZ17 mice with brainstem homogenates from paralyzed P301SxTAU62on mice. These 
seeded ALZ17 mice remained completely free of fibrillar tau pathology up to high ages. In contrast, seedings 
with P301S brainstem homogenates induced focal granular Gallyas-Braak silver stain-positive tau aggregates, 
as these homogenates also contain short tau filaments, known to be the most seeding-competent tau species 
(Jackson et al., 2016). The absence of fibril induction in ALZ17 mice inoculated with brainstem homogenates 
from paralyzed P301SxTAU62on mice confirms that early toxic tau oligomers can lack fibrillar tau seeding 
competence.   
At late disease stages, seeding-competent tau structures are present in most tauopathies, and capable of seeding 
fibrillar tau aggregates when injected into ALZ17 mice (Clavaguera et al., 2013). Interestingly, the only 
homogenates not provoking the formation of Gallyas-positive fibrils in ALZ17 mice, comparable to our 
P301SxTAU62on brainstem homogenates, were extracts collected from argyrophilic grain disease (AgD) 
patients. This has been linked to the histological predominance of pre-tangles over fully formed tangles in AgD 
(Ferrer et al., 2008), similar to the pre-tangle stage pathology present in our paralyzed P301SxTAU62on mice. 
A low seeding activity of AgD extracts has recently also been found in an RT-QuIC in vitro seeding model 
(Kraus et al., 2019). In that study, also brain extracts from other tauopathies exerted only low seeding effects, 
demonstrating the presence of non-, or not-yet seeding-competent tau forms in human tauopathies including 
progressive supranuclear palsy (PSP) and corticobasal degeneration (CDB) (Kraus et al., 2019). A comparably 
low seeding efficacy of PSP and CDB homogenates was found in a cell-based aggregation assay, while seeds 




caution when developing aggregation and seeding-based diagnostic assays. Very early tau forms could be 
toxic, but undetectable by seeding-based diagnostic tools.  
In conclusion, we here demonstrate that high molecular weight tau oligomers can provoke a severe, but 
reversible neurotoxicity. Rescued mice do not develop long-term sequelae, which argues for early therapeutic 
interventions targeting oligomeric tau forms. Furthermore, we confirm that these early toxic tau species lack 
classical seeding competence. Therefore, caution should be exercised when using seeding-based assays for the 
detection of very early preclinical tauopathy manifestations. Our findings also warrant a deepened analysis of 
early, non-fibrillar toxic tau forms in the future. While the knowledge on filamentous tau strains is rapidly 
growing thanks to Cryo-EM studies in particular (Fitzpatrick et al., 2017; Falcon et al., 2018a; Falcon et al., 
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Figure 1: Early neurotoxic stress depends on full length and ∆tau co-expression and is reversible.  
 
Fig.1: P301S heterozygous mice (P301Shet; n=5) at 21 days of age show no signs of paralysis in the tail 
suspension test, and histological tests with AT8 antibody did not detect hyperphosphorylated tau or Gallyas-
positive tau fibrils in the tegmental reticular nucleus (A). Hindlimbs of P301SxTAU62on (n=5) mice the same 
age as their heterozygous littermates are paralyzed; upon histological characterization, paralyzed 
P301SxTAU62on mice show hyperphosphorylated tau but no Gallyas-positive tau fibrils in the same region 
(B). After suspending doxycycline administration for 3 weeks, P301SxTAU62on-off (n=5) mice recover their 
motor functions and do not show hyperphosphorylated or fibrillar tau (C). Altogether, the findings confirm 
that the severe neurotoxicity in P301SxTAU62on mice does not depend on filamentous tau pathology, but 










Figure 2: Absence of tau filaments in paralyzed P301SxTAU62on mice 
 
Fig.2: Immunoelectron microscopy shows HT7-positive tau filaments in total tau and sarkosyl extracts of 
brainstem tissue from a 6-months-old homozygous P301S tau transgenic mouse (A). Total tau extract collected 
from a 3-weeks-old paralyzed P301SxTAU62on mouse reveals non-filamentous, oligomeric HT7 antibody 
positive tau structures while tau filaments are absent in its sarkosyl extract (B). Absence of tau aggregates in 
a 3-weeks-old BL6 control mouse (C). The findings confirm that the severe neurotoxicity in P301SxTAU62on 
mice does not depend on filamentous tau pathology, but is linked to hyperphosphorylated tau oligomers. Scale 













Figure 3: P301SxTAU62on-off mice do not develop an impaired motor phenotype upon aging.  
 
Fig.3: Tail suspension tests revealed normal hindlimb spreading for BL6 mice, and pathological hindlimb 
spreading predominantly in heterozygous P301S transgenic littermates at 16 months of age, while this was less 
pronounced in age-matched P301SxTAU62on-off (abbreviated P62on-off) mice (A). Rotarod test comparing BL6 
(n=10), P301Shet (n=15), and P301SxTAU62on-off mice (n=13) at 16 months of age revealed that 
P301SxTAU62on-off animals were not significantly more impaired than P301Shet mice which did not undergo 
early neurotoxic stress (B, P-value = 0,14). Grid tests of BL6 (n=10), P301Shet (n=17), and P301SxTAU62on-
off mice (n=11) at 16 months also showed that P301SxTAU62on-off mice were not experiencing heavier motor 
impairment when compared to their heterozygous littermates (C, P-value= 0,09). n.s. = P-value > 0,05; * = P-














Figure 4: Aged P301SxTAU62on-off mice show decreased hyperphosphorylated and fibrillar tau 
pathology compared to their heterozygous littermates.  
 
Fig.4: Histological tests comparing AT8 stained brainstem sections (A) of 16-months-old P301Shet (n=7) and 
P301SxTAU62on-off (abbreviated P62on-off) mice (n=7) revealed that the different performance in the behavioral 
tests was paralleled by different degrees of hyperphoshorylated tau pathology (B, P-value = 3,39E-06). These 
results were also mirrored by Gallyas-stained brainstem sections (C) of 16-months-old P301Shet (n=7), and 
P301SxTAU62on-off mice (n=7), which revealed different degrees of fibrillar tau pathology between the two 
groups (D, P-value = 7,77E-05). *** = P-value < 0,001. Scale bar equals 200 µm, and applies to A and C. See 













Figure 5: Aged P301SxTAU62off mice show lower total and soluble tau levels than their heterozygous 
littermates.  
 
Fig.5: Western blot analysis of total tau (HT7 antibody) revealed that P301Shet mice (n=5) have a significantly 
higher level of total tau when compared to P301SxTAU62on-off (abbreviated P62on-off) mice (n=5) at 16 months 
of age (A), which was confirmed by HT7/GAPDH ratio quantification (B, P-value = 1,32E-06). Soluble tau 
levels (C) in P301Shet mice (n=5) were also significantly higher than in P301SxTAU62on-off mice (n=5), as 
reflected by HT7/GAPDH ratio quantification (D, P-value = 0,0001). *** = P-value < 0,001. See also 










Figure 6: Total tau levels in young P301SxTAU62on-off mice do not decrease compared to their 
heterozygous littermates. 
 
Fig.6: Western blot analysis (HT7; A) and HT7/GAPDH ratio (B) for both P301Shet (n=6) and 
P301SxTAU62on-off (abbreviated P62on-off) mice (n=6). Tau levels were not significantly different between the 
two groups (P-value = 0,35). n.s. = P-value > 0,05. Box plots with hinges, whiskers and outliers. See also 













Figure 7: Seeding with high molecular weight tau results in complete absence of fibrils in ALZ17 mice. 
 
Fig.6: ALZ17 mice seeded with brainstem homogenates from paralyzed P301S homozygous (abbreviated 
P301Shomo) mice (n=5) revealed granular focal tau pathology in CA1 (A), which was not detected in ALZ17 
mice seeded with P301SxTAU62on brainstem homogenate (n=4). Granular focal tau pathology was also found 
in the fornix (B), and Gallyas-positive structures were detected in ALZ17 mice seeded with brainstem 
homogenates of paralyzed P301Shomo mice, but not in ALZ17 mice seeded with P301SxTAU62on brainstem 














Supplementary Figure 1: 
 
 
Suppl. Fig. 1: High magnification images extending the findings shown in Figure 1.  
P301S heterozygous mice (P301Shet; n=5) at 21 days of age show no signs of hyperphosphorylated tau or 
Gallyas-positive tau fibrils in the tegmental reticular nucleus (A). Paralyzed P301SxTAU62on mice (n=5) show 
hyperphosphorylated tau but no Gallyas-positive tau fibrils in the same region (B). After suspending 
doxycycline administration for 3 weeks, P301SxTAU62on-off mice (n=5) do not show hyperphosphorylated or 






Supplementary Figure 2: 
 
 
Suppl. Fig. 2: Schematic of background and main conclusions showing no long-term sequelae of reverted tau 
toxicity.  
P301SxTAU62on mice co-express human P301S mutant tau and, only under oral doxycycline (DOX) 
administration, ∆tau151-421 fragment. This results in hyperphosphorylated tau oligomers that cause a severe 
paralysis after 21 days. If these mice are fed normally, they only express heterozygous mutant P301S tau but 
not the tau fragment, and are thus comparable to P301Shet mice which remain without oligomeric tau 
formation or severe paralysis after 21 days. After expression of the doxycycline-responsive ∆tau151-421 fragment 
is switched off (P301SxTAU62on-off), hyperphosphorylated tau oligomers are cleared efficiently and mice 
recover their motor function in the following 3 weeks, even though mutant P301S tau expression is being 
maintained. Therefore, P301SxTAU62on-off mice exhibit a similar phenotype as P301Shet mice at three months 
of age. At 16 months of age, P301SxTAU62on-off mouse motor functions do not differ significantly from 




P301SxTAU62on-off compared to P301Shet mice. This proves that P301SxTAU62on-off mice do not experience 
sequelae of the early neurotoxic stress, when compared to their heterozygous P301S tau transgenic littermates. 
 
Supplementary Figure 3:  
 
Suppl. Fig. 3: High magnification images extending the findings shown in Figure 3.  
Aged P301SxTAU62on-off mice exhibit less AT8 and Gallyas-positive neurons than their heterozygous 
littermates. AT8 (A) and Gallyas silver (B) stained brainstem sections of 16-months-old P301Shet mice (n=7) 
show more hyperphosphorylated tau and silver stain positive pathology than P301SxTAU62on-off mice (n=7). 






Supplementary Figure 4:  
 
Suppl. Fig. 4: Immunohistochemistry targeting the AT100 phospho-epitopes at Thr 212 and Ser 214, and ∆tau 
(TauC3 antibody) in 16-months-old mice.  
In parallel to Gallyas silver stain positivity (Suppl. Fig. 3), extensive hyperphosphorylation of AT100-positive 
tau was seen in the brainstem of heterozygous P301S littermates (n=7) (A), but was almost absent in 
P301SxTAU62on-off mice (n=7)  (C). Immunohistochemistry with TauC3 antibody did not find any tau fragment 
in non-fragment expressing P301Shet mice  (n=7) (B), nor were signs of fragment expression leakage 
detectable in P301SxTAU62on-off mice (n=7) (D). The scale bar corresponds to 100 μm, and applies from A to 
D. 
 
Supplementary Figure 5:  
 
Suppl. Fig. 5: 3-months-old P301Shet and P301SxTAU62on-off mice do not show anti-tau antibodies in their 
sera.  
Dot blot with the sera of 3-months-old P301Shet (n=4) and P301SxTAU62on-off (labelled P62 on-off; n=3) mice 
was conducted, to test for the presence of anti-tau antibodies, using HT7 antibody as a positive control. 2N4R 






Supplementary Figure 6:  
 
Suppl. Fig. 6: Schematic of background and main conclusions showing that oligomeric toxic tau species can 
lack seeding competence.  
As positive control, ALZ17 mice were injected with tau fibril-containing brainstem homogenates of paralyzed, 
6-months-old P301S mice (left box). These ALZ17 control mice developed granular focal tau pathology in the 
injected hippocampus. Next, we analyzed the seeding capacity of oligomers resulting from co-expression of 
P301S tau and ∆tau151-421. To this end, we inoculated ALZ17 transgenic mice with brainstem homogenates 
collected from paralyzed, 3-weeks-old P301SxTAU62on mice, which do not show fibrillary tau pathology 
(right box). ALZ17 mice seeded with P301SxTAU62on mice brainstem homogenates did not develop focal tau 
aggregates in the inoculated hippocampus. This proves that brainstem tissue of paralyzed P301SxTAU62on 






Supplementary Table 1:  
TEST Mean time ± 
STD BL6  
Mean time ± 
STD  
P62on-off  









BL6               vs  
P62on-off 
P-value  




33 s ±  
8,77 s 
17,46 s ±  
12,78 s 
 












81,9 s ±  
65,14 s 
40,27 s ±  
38,84 s 











Suppl. Table 1: Overview on behavioral tests.  
The table shows the overview of the statistical values of the behavioral tests executed on P301S heterozygous 
mice (P301Shet), P301SxTAU62on-off mice (P62on-off) and BL6 mice; n.s = P-value > 0,05; * = P-value < 0,05; 






Supplementary Table 2:  
TEST Mean ± STD 
P301Shet 
Mean ± STD 
P62on-off 








0,50 ± 0,19 0,07 ± 0,04 7,77E-05 
(***) 
HT7/GAPDH signal total tau 
WB  16 months 
4,51 ± 0,24 2,88 ± 0,15 1,32E-06 
(***) 
HT7/GAPDH signal soluble tau 
WB 16 months 
3,23 ± 0,39 1,71 ± 0,31 0,0001 
(***) 
HT7/GAPDH signal 
WB 3 months 
1,32 ± 0,3 1,20 ± 0,17 0,35 
(n.s) 
 
Suppl. Table 2: Overview on immunohistochemistry and western blots.  
The table shows the overview of the statistical values of the quantified stained sections and western blots on 3 
and 16 months old P301S heterozygous (P301Shet) mice and P301SxTAU62on-off (P62on-off) mice; n.s = P-value 














Alzheimer’s disease (AD) is the most prevalent form of senile dementia with a global prevalence 
estimated to be above 30 millions (WHO, 2015). Its death toll is constantly rising, as it remains among 
the most frequent causes of death in the world, and the researchers even suspect that the official 
number are an underestimation of the real number of deaths associated to AD (James et al, 2014). 
Nowadays, the actual lack of therapeutic strategies resulting into useful treatments limits 
pharmacological therapies to symptomatic interventions, and with millions of people continuously 
diagnosed worldwide, AD is considered an enormous source of social, health and economic 
problems (Scheltens et al, 2016). 
Therefore, the research to understand the basic mechanisms behind the origin and development of 
the disease is fundamental, in order to establish successful therapeutic strategies to diminish its 
incidence. In this regard, AD has been particularly challenging. The pathological hallmarks of the 
disease have been established more than a century ago, since the observation of Prof. Alzheimer 
on fibrillary tangles and amyloid plaques. In time, the proteins constituting these neurological lesions 
have been identified, respectively, as the microtubule stabilizer tau and the resulting product from 
the processing of amyloid precursor protein (APP), amyloid β (Aβ).  
However, it has been more than 15 years since the last newly marketed drug against memory loss 
and AD (McShane et al, 2019), and during the years, therapies targeting Aβ have all failed soundly. 
Therefore, research has switched towards an increased attention on tau role on AD development. In 
this regard, tau recently-proven ability to seed pathological fibrils through anatomically connected 
regions (Clavaguera et al, 2009; Clavaguera et al, 2013) has opened new doors for the 
understanding of the disease and for hypothetical new therapeutic strategies stopping tau spreading. 
However, new aspects of tau pathology in AD have risen, particularly regarding the conformation of 
pathological tau, which is diversifying from the simple involvement of fibrils: tau toxicity has indeed 
been related also to oligomeric forms, which precede tau tangles and seem to be toxic by 
themselves. Furthermore, tau fragmentation has been found to participate to the neurotoxicity of 
both tau fibrils and oligomers, pointing the researchers’ attention also on cleavage patterns of the 
microtubule stabilizer. 
It is also difficult to diagnose AD, as the certainty of it comes only from post-mortem analysis, even 
though the quality of the diagnostic tests and instruments is constantly increasing. Apart from the 
imaging techniques and cognitive tests, biochemical biomarkers are becoming more reliable and 
suitable to track to understand the progression of the disease. On behalf of this, cerebrospinal fluid 




fragmented forms of tau also puts tau cleavage patterns into the spotlight for the understanding of 
the disease. 
 
4.1) Tau fragmentation and the role in tau oligomer-related toxicity 
The first presented results confirmed that high molecular weight tau oligomers cause a severe motor 
phenotype in tau transgenic mouse models, which is reversible and does not result neither in later 
motor adverse effects, nor in seeding effects. To conduct our study, we built a double transgenic 
mouse line, coming from previous papers published in our group, interbreeding P301S mice, carrying 
the mutant P301S mutation on MAPT gene (Allen et al, 2002), and TAU62 mice, which express 
∆tau151-421 fragment under a conditional Thy1,2 promoter, activated by doxycycline administration 
(Ozcelik et al, 2016). The resulting line, P301SxTAU62on mice, undergoes through a sever motor 
palsy, after three weeks, that can be reversed after stopping the expression of the ∆tau151-421 
fragment, while the expression of human mutant P301S tau is ongoing. This is obtained in three 
weeks after halting the administration of doxycycline. This early neurotoxic stress does not cause 
later adverse effects in the recovered P301SxTAU62on-off mice, neither in the form of motor 
impairments, nor in the form of tau tangles. Injecting P301SxTAU62on brainstem homogenates in 
ALZ17 mice did not result in tangles either, thus proving that our high molecular weight tau is not 
seeding competent. 
Tau oligomers have been proven to appear in the brain of AD patients (Lasagna-Reeves et al, 2012b) 
and progressive supranuclear palsy (Gerson et al, 2014). These oligomers have been shown to 
correlate well with neuronal death in aged mice (Lasagna-Reeves et al, 2011) and to correlate very 
well with clinical symptoms in AD patients, even more than tangles (Dujardin et al, 2020). Moreover, 
oligomers are generally thought to initiate disease development in tauopathies (Lasagna-Reeves et 
al, 2012) and even to appear before the first clinical symptoms (Maeda et al, 2006). Tau oligomeric 
toxicity has been hypothesized to depend on the conformation of the oligomers (Lo et al, 2019) and 
can also be aggravated by biological interactions with other complexes, such as chaperones (Oroz 
et al, 2018), RNA-binding proteins (Jiang et al, 2019), and nuclear complexes (Eftekharzadeh et al. 
2018); furthermore, immunological intervention against oligomers has shown to stop tau seeding in 
vitro (Abskharon et al, 2020). Based on this, oligomeric tau species are now considered to play a 
central role in the pathogenesis of neuronal dysfunction in tauopathies (Ghag et al, 2018; Polanco 
et al, 2018; Sengupta et al, 2017; Bittar et al, 2019), comparably to oligomeric structures in other 
neurodegenerative disorders (Hong et al, 2018; Sekiya et al, 2019). 
The severe early neurotoxic stress experienced by P301SxTAU62on-off mice strengthens this 
hypothesis as it relies solely on tau oligomers and can be reversed by cleaning said tau oligomers, 




neurotoxic stress, we found that these mice exhibit a less pronounced motor phenotype at 14 and 
16 months of age compared to their heterozygous P301S littermates that did not experience previous 
compelling neurotoxicity. Aged P301SxTAU62off also show an absence of increased tau pathology, 
no formation of tangles, and less total and soluble tau protein levels compared to P301Shet mice.  
Our P301SxTAU62on-off model therefore suggests that there is no later effect after clearing the mice 
of high molecular weight tau forms consisting of toxic oligomers, even while still expressing a mutant 
human tau form, such as P301S tau.  
To our knowledge, this is a surprising result when compared to previous studies in mouse models 
with conditional expression of mutant human tau, as recovery of mice was obtained only by 
suppressing the expression of said mutant tau forms (Polydoro et al, 2013; Wang. X et al, 2018; Van 
der Jeugd et al, 2012). Previous studies in rTgTauEC mice have shown that NFT-associated toxicity 
can be reversed by suppressing tau overexpression (Polydoro et al 2013),  and that early intervention 
in rTg4510 mice (Wang. X et al, 2018) and in pro-aggregant hTau40 mice (Van der Jeugd et al, 
2012) can improve the motor fitness of these models when suppressing mutant human tau forms. In 
our study, tau neurotoxicity is unrelated to tangles and it is reversed by halting ∆tau151-421 fragment 
expression alone. Our P301SxTAU62on-off mice do not need to suppress mutant human P301S tau 
heterozygous expression to recover from early neurotoxic stress and maintain their motor function 
in later stages of life, thus showing that mutant tau expression can be tolerated even in adult age if 
high molecular weight toxic combinations of tau have been previously cleared from the mouse brain.  
It is important to remark that clearance of tau oligomers in P301SxTAU62on-off mice surprisingly does 
not result into any later development of pathological tau forms. Previous studies in rTg4510 mice 
have shown tau tangles could be dissociated from neuronal dysfunction (SantaCruz et al, 2005); 
particularly, cognitive functions are recovered once expression of transgenic P301L tau is halted, 
but tau tangles continue to accumulate (SantaCruz et al, 2005). Our findings confirm that early tau 
neurotoxicity can occur in the absence of tangles and is potentially reversible, but more importantly, 
we here show for a first time that reversible soluble neurotoxic tau species do not necessarily lead 
to formation of tangles as long term sequelae after the neurotoxic stress. This adds further 
knowledge on mutant human tau progression in mouse models and may bring to new therapeutic 
strategies in human patients. It is known in humans that tau oligomers appear in prefrontal cortex at 
Braak stage 1, preceding the formation of tangles (Maeda et al, 2006) which are confined in trans-
entorhinal cortex at that stage (Braak & Braak, 1991). Oligomers are thought to act as intermediates 
for assembly of tangles in later Braak stages (Maeda et al, 2007). Stopping their conversion to NFT 
in mice by acting with small molecule compounds on tau oligomers reduced neuronal loss and 
reversed brain dysfunction (Soeda et al, 2015), thus giving hope that halting oligomer-related toxicity 




To test whether or not our toxic tau forms were seeding competent, we injected brainstem 
homogenates containing high molecular weight tau species of P301SxTAU62on mice in ALZ17 mice, 
devoid of fibrillary pathology. This resulted in ALZ17 mice being completely free of fibrillary tau 
pathology, particularly when compared to the same mice seeded with P301S brainstem 
homogenates, which show focal granular pathology in CA1 and fornix. Our experiments therefore 
prove that toxic tau oligomers do not necessarily have to be seeding competent and this early co-
expression might halt seeding competence of tau oligomers and spreading of tau pathology through 
anatomical networks in the brain.  
Tau spreading mechanisms are not fully understood yet (Mudher et al, 2017). Tau propagation has 
been shown to occur in different ways comparing various tauopathies (Sanders et al, 2014). Seeding 
experiments with P301SxTAU62on brainstem homogenates follow previous similar experiments with 
brainstem homogenates of various tauopathies being injected into the same fibrils-free ALZ17 mice 
(Clavaguera et al 2013). Our particular combination of Δtau151-421 and mutant P301S tau was 
previously proven as highly neurotoxic but not fibrillogenic, and here we add further results showing 
that it does not have any seeding potential when injected in ALZ17 mice, thus proving that high 
molecular weight toxic tau species can also be not-seeding competent. 
Many fibrillogenic brainstem homogenates proved capable of spreading tau fibrils when injected into 
ALZ17 mice (Clavaguera et al, 2013); interestingly, the only ones not yielding Gallyas-positive fibrils, 
just like our injected P301SxTAU62on brainstem homogenates, were argyrophilic grain disease 
(AGD) extracts. This could have been linked to AGD histological features, consisting mainly of pre-
tangles rather than fully formed tangles (Ferrer et al, 2008). It may be that Gallyas-negative brain 
extracts, or extracts containing very few tangles, are not able to cause formation of fibrils and their 
subsequent spreading in mice. Previously, tau oligomers prepared in vitro have been proven to 
propagate when injected in BL6 mice, and cause neurodegeneration and β-sheet-rich neurotoxic 
aggregates (Lasagna-Reeves et al, 2011). β-sheet structures were also proven to be necessary for 
mutant human P301S tau aggregation in transgenic mice (Macdonald et al, 2019). Our 
P301SxTAU62on brainstem homogenates may not seed due to the inability of our high molecular 
weight tau oligomers to form enough β-structures and induce tau aggregation in ALZ17 mice.  
Another explanation could be related to cellular mechanism of propagation, as tau is mainly thought 
to spread thanks to exosomal secretion (Wang. J et al, 2017). This same process can lead tau to 
cerebrospinal fluid (Saman et al, 2012), without losing its seeding potential (Skachokova et al, 2019). 
This shows that exosomes maintain seeding capacity through different anatomical networks and 
brain compartments, even though tau is differentially phosphorylated in said exosomes compared to 
pathological brain cells (Polanco et al, 2016). It is possible that our specific high molecular weight 




Oligomer-related toxicity, particularly related to fragmentation is not unprecedented in 
neurodegenerative diseases. The second most common neurodegenerative disorder in the world, 
behind AD, is Parkinson’s disease (PD) (Blauwendraat et al, 2020), which is characterized by a 
massive cell death of dopaminergic neurons in the substantia nigra caused by pathogenic inclusions 
known as Lewy bodies (Deuschl & deBie, 2019). However, it has also been hypothesized that 
oligomers could initiate toxic pathways in PD as well (Chen et al, 2015). β-sheets oligomers cause 
a significant loss of dopaminergic neurons (Meade et al, 2019), and fragments of α-synuclein can 
contribute decisively to fibrillogenic aggregation in PD (Guerrero-Ferreira et al, 2018). The link 
between fragmentation and oligomerization was recently established more in detail, when it was 
proven that fragments of α-synuclein can recruit monomers to constitute pathogenic oligomers and 
even worsen the pathological condition in mouse models of PD (Froula et al, 2019). The intervention 
on said fragments was shown to halt the aggregation of fibrils and to have a therapeutic potential 
against PD (Froula et al, 2019). 
Another similar case of pathogenic assembly linked to fragmentation, particularly complexing full-
length proteins and fragments, occurs in TDP-43 proteinopathies, such as amyotrophic lateral 
sclerosis (ALS) (Wang.X et al, 2015; Li.Q et al, 2015). Although the pathogenic mechanism of ALS 
has yet to be fully understood, TDP-43 accumulates into cytoplasmic inclusions which are highly 
cytotoxic; particularly, the aggregates are formed mainly by the full-length protein and a 25 kDa C-
terminal fragment (CTF-25), which appears to be highly neurotoxic (Li.Q et al, 2015).   This CTF-25 
fragment is thought to enhance endoplasmic reticulum (ER) stress-mediated apoptosis in the 
neurons, thus increasing neuronal cell death (Wang.X et al, 2015). Recently, toxic oligomers formed 
by TDP-43 have also been linked to aggregation initiation in ALS (French et al, 2019), and it is 
coherent with previous observations of C-terminal fragments of the same protein guiding pathological 
aggregation (Shimonaka et al, 2016), thus also bringing to light a possible link between 
fragmentation, oligomerization and initiation of neurotoxic pathways. Altogether, the results 
presented in the thesis follow therefore nascent lines of research where oligomers are questioning 
the importance of established hallmarks in neurodegenerative diseases, and oligomerization might 
be indeed linked to fragmentation of protein at the center of neurological proteinopathies. 
 
4,2) CSF tau and its seeding properties  
The second presented results followed previous studies on the seeding properties of CSF-derived 
amyloid aggregates of our group, and goes further in the analysis by testing CSF-derived tau and its 
seeding capabilities. Our quest for the evidence for in vivo seeding activity of CSF tau follows recent 
findings on the ability of CSF tau to induce seeding-like conformational changes in vitro (Saijo et al, 




patients have been inducing tau aggregation in HEK293 cells expressing a P301S tau repeat domain 
(Takeda et al, 2016). CSF tau derived from Pick’s disease patients has furthermore been found to 
induce real-time quacking conversion of a 3 repeat tau fragment (Saijo et al 2017). In vitro seeding 
activity in cellular systems, or prion-like substrate conversion capacity by real-time quacking induced 
conversion (RT-QuIC), has furthermore recently been demonstrated for CSF in the context of other 
neurodegenerative proteinopathies, including sporadic Creutzfeld Jakob Disease (CJD) (Foutz et al, 
2017), and Huntington’s Disease (HD) (Tan et al, 2015). 
We therefore investigated in vivo seeding properties of CSF tau. Particularly, we tested whether 
human CSF from AD patients exhibits signs of in vivo seeding competence when inoculated into 
P301S mice. In the setting of an explorative clinical trial, high volume samples of 15ml CSF were 
collected from 23 consecutive patients of an outpatient memory clinic. Out of this prospective cohort, 
we identified 5 patients fulfilling the criteria for “Probable AD dementia” or MCI – core clinical data”, 
constituting the AD group, and 4 age-matched patients with a diagnosis “Dementia-unlikely to be 
due to AD” or “MCI-unlikely due to AD” (McKhann et al, 2011), attributable to the control group.  
AD patients’ derived CSF provoked a significant increase in hippocampal tau hyperphosphorylated 
neurons, as well as a significant increase in Gallyas positive hippocampal neurons. Furthermore,  
injection of concentrated human AD CSF samples into pre-tangle stage P301S mice resulted in focal 
granular, dot-like tau accumulation particularly in the fimbria and the dentate gyrus in a subset of the 
inoculated mice, very similar to earlier findings in PS19 mice seeded with brain extracts from a 
human CBD patient (Boluda et al, 2015). Punctate Gallyas silver staining positive dot-like structures 
indicative of axonal tau aggregates accumulated in the dorsal fornix ipsilateral to the injection site in 
two AD-CSF inoculated mice, reminiscent of a similar pathology induced in the fornix of P301S mice 
seeded with P301S donor brain extracts (Ahmed et al, 2014).  
The reported seeding competence of CSF tau contrasts our earlier aforementioned findings in 
seeding experiments with Aβ. There, extensive long-term seedings, inoculating concentrated human 
or murine Aβ comprising CSF into APP transgenic host mice, failed to provide evidence for the 
presence of bioactive Aβ seeds in the CSF compartment (Fritschi et al, 2014; Skachokova et al, 
2015). The here found biological seeding activity of CSF tau is however not entirely surprising. In 
contrast to Aβ that aggregates broadly in the brain parenchyma and the perivascular space, tau is 
readily drained towards the CSF compartment. Opposite to Aβ, tau levels increase in the CSF with 
progressive Alzheimer’s disease (Olsson et al, 2016). Tau is also known to be present in the CSF 
compartment in its post-translationally modified, hyperphosphorylated form, as a first evidence of an 
efflux of pathologically altered tau species from the brain towards the CSF.  
The presence of bioactive tau seeds in the CSF of AD patients suggests a diagnostic use of the 
aggregation induction capacity of CSF tau in tauopathies. In contrast to brain tissue, CSF can easily 




et al, 2017). The simple analysis of CSF tau levels is an established part of the diagnostic criteria for 
AD, but it lacks yet high specificity and is unable to provide prognosis at early or even pre-
symptomatic disease stages (Olsson et al, 2016). The latter would however be important also for the 
development of novel therapies. Our detection of bioactive tau seeds in human CSF of AD patients 
augurs well for the development of novel diagnostic tools that are based on the specific 
conformational properties and the bioactivity of tau.  
The biological in vivo seeding capacity of AD patients’ CSF we here describe asks for considerations 
on the biosafety of operators when handling human CSF samples. Taking into account that, 
compared to previous seedings with brain tissues (Clavaguera et al 2013), relatively mild seeding 
effects occurred after inoculation of concentrated CSF into an artificially tau overexpressing murine 
host system, we would still consider the seeding potential of human AD tau in CSF rather low, and 
of limited relevance in a routine laboratory or clinical setting when adhering to standard safety 
procedures for the handling of potentially infectious human biosamples.    
Our results come however from a study subject to some limitations. Due to the high amounts of 
human CSF needed to allow its concentration, CSF had to be collected from consecutively donating 
patients. This resulted in a small number of patients’ samples attributable to either the AD or the 
group, similar to the previous in vitro study done in HEK293 cells (Takeda et al 2016). As all patients 
were similarly aged, we furthermore can’t exclude that patients attributed to the control group were 
subjected to pre-symptomatic, yet possibly seeding competent tau pathology, and thereby might 
have lessened the differences between the AD and the control group. As tau seeding is a time and 
concentration dependent process (Clavaguera et al 2009), we concentrated the CSF samples before 
the intracerebral inoculations. It might be, therefore, that the seeding potential of tau was increased 
by the concentration process itself. The absence of any seeding activity in our previous experiments 
with concentrated CSF-Aβ (Fritschi et al 2014, Skachokova et al 2015), as well as the significant 
differences between the CSF tau derived from P301S mice and AD patients versus the controls, 
however speak against a relevant influence of the concentrating step. Given the life span of 
homozygous P301S host mice, the maximum seeding time is limited to 4 months. We therefore can 
not exclude that a more robust seeding response would become apparent at later times points post-
seeing.  
The exact nature of bioactive tau seeds has yet remained unknown. The need of high amounts of 
CSF seeding in the present study has precluded any detailed analysis of the bioactive seeds. In their 
post mortal CSF samples, Takeda et al. found high molecular weight tau (HMW) species and 
considered them to be the bioactive species (Takeda et al 2016). HMW tau species were however 
also detectable in one of the control patients, what might be due to post mortal tau aggregation given 
their CSF sampling at autopsies. The next steps should therefore analyze the biochemical and 




Recent studies correlated tau truncated at residue 368 in the CSF compartment with tau PET 
analysis (Blennow et al, 2020), stating that the aforementioned fragment correlates well with tau 
pathology in AD patients (Blennow et al, 2020). Other studies focused on the relationship between 
tau truncation at residue 224 in the CSF compartment and AD, suggesting a strong association 
(Cicognola et al, 2019). Both these fragments seem to be part of tau tangles (Blennow et al, 2020; 
Cicognola et al, 2019), thus suggesting that CSF tau forms can be seeding competent, possess an 
aggregating nature and, again, are mainly present and relevant in cleaved forms. CSF-derived tau 
has been also recently linked to mnemonic worsening by itself, as higher levels of CSF tau were 
associated with a worse memory performance in old adults (Berron et al, 2019). With other studies 
previously hinting at a correlation between levels of specific forms of tau in CSF, such as tau 
phosphorylated at Thr231, and cognitive decline (Ashton et al, 2020), CSF-derived tau could 
therefore clarify many doubts regarding diagnostic procedures for AD patients, once its seeding 
properties, and its correlation to cognitive features is further elucidated. 
As said before, studies on the diagnostic value of CSF tau in AD mirror other approaches in the 
various neurodegenerative diseases, particularly CJD and HD (Foutz et al, 2017; Tan et al, 2015). 
Adding to the aforementioned RT-QuIC  studies, reducing prion levels in the CSF has been recently 
shown to be a good option to test the efficacy of prion-reducing drugs in the CNS (Vallabh et al, 
2019), thus suggesting that prion protein levels in CSF could be used as a pharmacodynamic 
biomarker (Vallabh et al, 2019). CSF mutant huntingtin levels were instead related to HD stages and 
the presence, in the central nervous system, of mutant huntingtin (Southwell et al, 2015), with CSF 
mutant huntingtin increasing along with the stage of the disease (Southwell et al, 2015). 
Pharmaceuticals companies, developing pioneering antisense oligonucleotides targeting mutant 
huntingtin, used CSF levels of that same mutant protein to test the efficacy of the treatment in the 
various phases of the trials (Mullard, 2019b), thus speaking highly of the reliability of huntingtin 
measurements in CSF related to HD stages.  
Altogether, these findings advocate for an increasing importance of CSF biomarkers for many 
neurodegenerative diseases, thus underlying the need for further research on the mechanisms 
bringing aggregation-prone proteins, and most likely fragments of them, to the CSF compartment, 
and the consequent relevance for the diagnostic tools available to clinicians. The results presented 
into the thesis follow this research direction and provide a little, but significant advancement in the 
understanding of CSF-derived tau properties, establishing its seeding competence and its possible 
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ABri = Amyloid-Bri 
AD = Alzheimer’s disease 
ADan = Amyloid-Dan 
AGD = Argyrophilic grain disease 
ALS = Amyotrophic lateral sclerosis 
ApoE4 = Apopoliprotein E4 
APP = Amyloid precursor protein 
Aβ = Amyloid beta 
BACE = Beta-site APP cleaving enzyme 
BBB = Blood brain barrier 
CaMKII = Calcium or calmodulin-dependent protein kinase II 
CBD = corticobasal degeneration 
Cdk5 = Cyclin-dependent kinase-5 
CDR = Clinical Dementia Rating 
CJD = Creutzfeld Jakob Disease 
CK1 = Casein kinase 1 
CNS = Central nervous system 
CSF = Cerebrospinal fluid 
CTE = Chronic traumatic encephalopathy 
EEG = Electroencephalography 
EOAD = Early onset Alzheimer’s disease 
ER = Endoplasmic reticulum 
FBD = Familial British dementia 
FDD = Familial Danish dementia 
FTDP-17 = Frontotemporal dementia and parkinsonism linked to chromosome 17 
FTLD = Frontotemporal lobar degeneration 
GGT = Globular glial tauopathy 
GSK-3 = Glycogen synthase kinase-3 
HD = Huntington’s disease 




HMW = High molecular weight 
LOAD = Late onset Alzheimer’s disease 
MAPK = Mitogen-activated protein kinase 
MARK = Microtubule affinity-regulating kinase 
MCI = Mild cognitive impairment 
MMS = Mini Mental State 
MMSE = Mini-Mental State Examination 
MOCA = Montreal Cognitive Assessment 
MRI = Magnetic resonance imaging 
NFL = Neurofilament light protein 
NFT = Neurofibrillary tangles 
OGT = O-GlcNAc transferase 
PART = Primary age-related tauopathy 
PD = Parkinson’s disease 
PDPK = Proline-directed protein kinases 
PET = positron emission tomography 
PFA = Paraformaldehyde 
PHF = Paired helical filaments 
PKA = Cyclic AMP-dependent protein kinase 
PSEN 1 = Presenilin-1 
PSEN 2 = Presenilin-2 
PSP = Progressive supranuclear palsy 
PTM = Post-translational modification  
RT-QuIC = Real-time quacking induced conversion 
sAPPβ = Soluble amyloid precursor protein beta 
SF = Straight filament 
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